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INTRODUCTION 
Quality assurance (QA) plays a central role in determining the safety and 
efficacy of medicines and it refers to the planned and systematic activities that are 
implemented in a quality system so that quality requirements for a product are fulfilled. 
It is the systematic measurement, comparison with a standard, monitoring of processes 
and an associated feedback loop that confers error prevention. This can be contrasted 
with Quality "Control" which is focused on process outputs. 
 
Quality Control (QC) is a system of routine technical activities, to measure and 
control the quality of the inventory as it is being developed. Highly specific and sensitive 
analytical techniques hold the key to the design, development, standardization and 
quality control of medicinal products. Quality level of any analytical work in a quality 
control laboratory depends on expertise of the analyst, most appropriate analytical 
procedure and overall performance of the analytical instruments. 
 
 The QC system is designed to: 
 Provide routine and consistent checks to ensure data integrity, correctness and 
completeness; 
 Identify and address errors and omissions; 
 Document and archive inventory material and record all QC activities. 
 
The main task of the pharmaceutical analyst is to provide reliable analytical data 
rapidly and as accurately as required, repeatedly at low cost and on a wide range of 
different samples, raw materials and formulations. 
 
Analytical chemistry is the study of the separation, identification, and 
quantification of the chemical components of natural and artificial materials ie., it  deals 
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with the qualitative and quantitative determination of chemical components of 
substances.  Modern analytical chemistry has the most diverse methods and techniques 
of analysis for quantitative determination. 
 
Significance of analytical chemistry 
 Analytical chemistry has played critical roles in the understanding of basic 
science, biomedical applications, environmental monitoring, quality control of 
industrial manufacturing, forensic science and so on. 
 Analytical chemistry has been an indispensable area in the development of 
nanotechnology. 
 Impurity profiling of the drug 
 Stability indicating degradation studies 
 Chiral separation of enantiomers and analyzing which enantiomer is responsible 
for the activity 
 Bio analytical studies became simpler and easy to perform by the emergence of 
hyphenated analytical techniques  
 Structure elucidation of newly synthesized drug or isolated from natural origin.  
 Control of the purity of the raw material thus making cost effective synthesis of 
drugs. (Anonymous www.acs-analytical.duq.edu/whatisanalyticalchem.html)  
 
Methods of analysis are routinely developed, improved, validated, studied and 
applied. Modern methods of analysis are sensitive, providing precise and accurate 
information about the standards of chemicals or drugs upto nanogram levels.  
The main task of analytical chemist is to provide reliable analytical data 
accurately, repeatedly at low cost on wide range of raw material and formulations.   
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Methods of analytical chemistry includes 
• Classical methods (Wet-chemical methods) 
            The compound of interest is separated by precipitation or extraction or 
distillation. Further they are subjected to qualitative or quantitative analysis. 
 Qualitative analysis 
        Qualitative analysis gives an indication of the identity of the chemical species in 
the sample. Separated components treated with reagents that yield product that could be 
recognized by color, boiling point, melting point, solubility in a series of solvents, odour, 
optical activity and refractive index. 
 Quantitative analysis 
Quantitative analysis determines the amount of molecule qualitatively detected 
present in the compound being analysed (Willard, et al., 1986; P.D.Sethi, et al., 2001; 
Douglas A. Skoog, et al., 2004). The separated components are analyzed by  
Gravimetry which involves methods of weighing after extraction, derivative 
separation, residue after ignition and 
Titrimetry which include acid- base precipitation, redox, complexometric, 
diazotization, aqueous and non aqueous titrations. 
 
• Instrumental methods 
Based on the measurement of the physical properties of the analyte, the following 
techniques are used. 
 Electro chemistry Conductometry, potentiometry, amperiometry 
 Spectrophotometry Absorption and emission spectrophotometry 
 Mass to charge ratio Mass spectroscopy   
 Flourescence Flourimetry 
 Chromatography LC, HPLC, HPTLC, GC 
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 Electrophoretic techniques Capillary, zone, paper electrophoresis 
 Hypenated techniques GC-MS, LC-MS, LC-MS/MS, LC-DAD-MS 
Analytical Method Validation (Code Q2A- ICH Guidelines 1996 & IP 1996) 
 Validation of an analytical method is the process that establishes, by laboratory 
studies, that the performance characteristics of the method meet the requirement for the 
intended applications. For pharmaceutical analytical methods, guidelines from the United 
States pharmacopeia (USP) international conference on harmonization (ICH) and food 
and drug administration (FDA) provide a frame work for performing such validations.    
 
Reasons for validation 
 As quality control process is not static, some form of validation/verification 
should continue till the validated process is in use. 
 Closer interaction with pharmacopoeia harmonization particularly in respect to 
determination of impurities and their limits. 
 Setting standards of evaluation procedure for checking complaints and taking 
remedial measures. 
 Retrospective validation is useful for trend comparison of results compliance to 
cGMP/GLP 
 Enables scientists to communicate scientifically and effectively on technical 
matters. 
Analytical parameters for assay validation as per ICH guidelines (USP 2000) 
 Accuracy 
 Precision 
• Repeatability 
• Intermediate precision 
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• Reproducibility 
 Specificity 
 Limit of detection 
 Quantitation limit 
 Linearity  
 Range 
 System suitability 
 Robustness 
 Ruggedness 
 
Accuracy 
The accuracy of an analytical method is the extent to which test results generated 
by the method and the true value agree. Accuracy can also be described as the closeness 
of of the measured value to the true value.  
Accuracy is calculated as the percentage of recovery by the assay of the 
knownadded amount of analyte in the sample (spiked sample), or as the difference 
between the mean and the accepted true value, together with confidence interval. 
Accuracy is usually performed in triplicate at three levels over a range of 50 to 150% of 
the target concentration. (Analytical chemistry 1996) 
 
Precision 
 
 It may be measure of either the degree of reproducibility, intermediate precision 
or repeatability of the analytical method under normal operating conditions.  It is usually 
expressed as SD (Co-efficient of variation) of a series of measurements. 
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 Repeatability refers to the use of analytical procedure within the laboratory over a 
short period of time using the same analyst with same instrument. 
 Reproducibility refers to the use of analytical procedure in different laboratories 
as in a collaborative study. 
 Intermediate precision expresses within the laboratory variation, as on different 
days or with different analysts or equipment within the same laboratory. 
 ICH documents recommend that repeatability should be assessed using minimum 
of nine determinations covering the specified range for the procedure (i.e., three 
concentrations and three replicates of each concentration) a minimum of six 
determinations at 100% of the test concentration. 
 
Specificity 
 It is the ability to assess the analyte within the presence of components, such as 
impurities, synthesis intermediates, excipients, degradation products etc. in comparison 
with the response of the standard analyte. 
 
Detection Limit (LOD) 
 It is the lowest amount of analyte in the sample that can be detected, but not 
necessarily quantified as an exact value. 
 Based on the standard deviation of the response and the slope the detection limit 
(LOD) may be expressed as  
S
LOD σ3.3=  
 Where, σ - standard deviation of the response, 
  S – Slope of the calibration curve (of the analyte) 
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Quantitation Limit (LOQ) 
 It is the lowest amount of analyte in the sample that can be determined with 
acceptable precision and accuracy under the stated experimental conditions.  
 The quantitation limit is expressed as the concentration of analyte (eg: percentage 
parts per million) of the sample. 
S
LOQ σ10=  
 Where, σ - standard deviation of the response, 
  S – Slope of the calibration curve (of the analyte) 
 
Linearity 
 The linearity of an analytical method is its ability to elicit test results that are 
directly proportional to the concentration of analytes in samples. Acceptability of 
linearity data is judged by the correlation coefficient and intercept of the linear 
regression line for the response versus concentration plot.  
 
Range 
 Range of a method is the interval between the upper and the lower levels of 
analyte (including these concentrations) that have been demonstrated to be determined 
within a suitable level of precision, accuracy and linearity. 
 
Sensitivity 
 The sensitivity of an analytical method is the capability of the method to 
discriminate small differences in concentration or mass of the test analyte. In practical 
terms, sensitivity is the slope of the calibration curve that is obtained by plotting the 
response against the analyte concentration or mass. 
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Ruggedness 
Ruggedness is a measure of reproducibility of test results under normal, expected 
operational conditions from laboratory to laboratory and from analyst to analyst. 
Ruggedness is determined by the analysis of aliquots from homogeneous lots in different 
laboratories. 
 
Robustness 
Robustness tests examine the effect that operational parameters have on the 
analysis results. For the determination of a method’s robustness, a number of method 
parameters, for example, pH, flow rate, column temperature, injection volume, detection 
wavelength or mobile phase composition, are varied within a realistic range, and the 
quantitative influence of the variables is determined. If the influence of the parameter is 
within a previously specified tolerance, the parameter is said to be within the method’s 
robustness range.  
 
System suitability parameters for HPLC analysis (Anonymous-U.S.P, 1995) 
  The purpose of the system suitability test is to ensure that the complete testing 
system (including instrument, reagents, columns, analysts) is suitable for the intended 
application.  
  System suitability tests are an integral part of gas and liquid chromatographic 
methods. They are used to verify that the resolution and reproducibility of the 
chromatographic system are adequate for the analysis to be done. 
Capacity factor k’ > 2 
Injection precision RSD < 1% for n > 5 
Resolution Rs  > 2 
Tailing factor T  < 2 
Theoretical plate N  > 2000 
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Retention time (Rt) is the time of emergence of the maximum of a component after 
injection. 
Symmetry factor or tailing factor (T) is a measure of peak symmetry, is unity for 
perfectly symmetrical peaks. Its value increases as tailing become more pronounced. As 
peak asymmetry increases, integration and hence precision, becomes less reliable. 
The tailing factor can be determined by using the equation, 
f
WT
2
05.0=  
Where, W0.05 is the width of the peak at 5% height 
 f is the distance from the peak maximum to the leading edge of the peak, 
when measured at 5% peak height (from the baseline). 
 
Number of theoretical plates (N) is a measure of column efficiency. If the number of 
theoretical plate is high, the column is said to be highly efficient and vice versa. It is a 
measure of sharpness, which is important for the detection of trace elements. 
  2
2/1
54.5 





=
w
tN  
The assessment of performance of efficient of a column is in terms of number of 
theoretical plates. 
 
Resolution is a measure of relative separation of two plates. Resolution is defines as the 
distance between the two band centers divided by the average width of the peaks 
determined at the bases of peaks. 
 
Resolution can be determined using the equation 
21
21 )(2
WW
ttR
+
−
=  
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Where, 
t1 and t2 are retention time of first component and second component 
respectively. 
W2+W1 are width of peak of first component and second component eluted. 
Statistics in Analytical Chemistry 
 Statistics (Skoog, 2006) is the science of making effective use of numerical data 
relating to groups of individuals or experiments.  It is the quantitative science, meaning 
that desired result is almost always numeric. 
Quantitative results are obtained using devices or instruments that allow us to 
determine the concentration of a chemical in a sample from observable signal.  One of 
the uses of statistics in analytical chemistry is to provide an estimate of the likely value 
of that error, in otherwords, to establish the uncertainty associated with the measurement. 
Statistical Parameters (Gupta, 1994)  
 The precision or reproducibility of the analytical method was determined by 
repeating the analysis and the following statistical parameters were calculated. 
Mean 
 The Mean or average is obtained by dividing the sum of observed values by the 
number of observations (n).  
n
X
x ∑=  
Standard Deviation (SD) 
 Standard deviation is measure of data dispersion or variability. The standard 
deviation gives an idea of how close the entire set of data is to the average value. SD is 
also called root mean square deviation. 
∑ −−= 1/)( 2 nXXSD  
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Relative Standard Deviation (RSD) 
 The relative standard deviation is also called co-efficient of variation. This is 
useful when the SD is proportional to the magnitude of the measurement. It is defined as  
X
SDRSD =  
100% ×=
X
SDRSD  
 
Regression Equation 
 A regression is a statistical analysis assessing the association between two 
variables. It is used to find the relationship between two variables.  
Regression equation cmxy +=  
Where, m – the slope of regression line 
   c – the intercept point of regression line and the y axis 
 
Standard Error 
Standard error is a statistical term that measures the accuracy with which a 
sample represents a population. In statistics, a sample mean deviates from the actual 
mean of a population; this deviation is the standard error 
 Standard error (SE) is given by      
n
SDSE =  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
Review of Literature 
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REVIEW OF LITERATURE 
 
OMEPRAZOLE 
 
Kobayashi K., et al., (1992) performed simultaneous determination of 
omeprazole and its metabolites in plasma and urine by reversed-phase high-performance 
liquid chromatography with an alkalin resistant polymer coated C18 column.  
Chilukuri., et al., (1997) developed spectrophotometric methods for the 
determination of omeprazole in bulk and pharmaceutical dosage forms. Four methods 
were  developed based on the  formation of colored species by treating  omeprazole with 
3-methyl-2-benzothiazolinone hydrazone (MBTH) following oxidation with ferric 
chloride (method A) or m-aminophenol following oxidation with chloramine-T (CAT) 
(method B) or Folin-Ciocalteau reagent (FC) (method D), or by oxidizing OMZ with 
excess N-bromosuccinimide (NBS) and determining the consumed NBS with a decrease 
in color intensity of Celestine blue (CB) (method C) 
Karljikovic-Rajic, K., et al., (2002) developed a first order UV-derivative 
spectrophotometry in the analysis of omeprazole and pantoprazole sodium salt and 
corresponding impurities. Zero-order crossing method was developed in methanol-
ammonia 4.0% v/v, where sufficient spectra resolutions of drug and corresponding 
impurity were obtained using the amplitudes 1D304, 1D291.5 respectively. Zero crossing 
method showed the impurity – drug intermolecular interactions, due to the possible 
intermolecular hydrogen bonds. 
Abdel Aziz Wahib, M., et al., (2002) developed spectrophotometric 
determination of omeprazole, lansoprazole and pantoprazole in pharmaceutical 
formulations. The compensation method and other chemometric methods (derivative, 
orthogonal function and difference spectrophotometry) have been applied to the direct 
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determination of omeprazole, lansoprazole and pantoprazole in their pharmaceutical 
preparations. The methods have been validated; the limits of detection were found to be 
3.3×10−2, 3.0×10−2 and 3.5×10−2 μg ml−1 for the three drugs, respectively. 
Salama, F., et al., (2003) validated spectrophotometric determination of 
omeprazole and pantoprazole sodium via their metal chelates. The procedures are based 
on the formation of 2:1 chelates of both drugs with different metal ions. The coloured 
chelates of omeprazole in ethanol are determined spectrophotometrically at 411, 399 and 
523nm using iron(III), chromium(III) and cobalt(II) respectively. 
Lakshmi sivasubramanian, et al., (2007) proposed a method for the 
simultaneous HPLC estimation of omeprazole and domperidone from tablets. The 
determination was carried out on a hypersil, ODS, C-18 (150x4.6mm, 5 micron) column 
using a mobile phase of methanol: 0.1M ammonium acetate (pH4.9) (60:40).  Eluent was 
monitored at 280nm. 
Akheel Ahmed Syed, et al., (2007) derived spectrophotometric methods using 
new reagents such as neocuproine and bathocuproine for the determination of antiulcer 
drugs namely omeprazole, lansoprazole, pantoprazole, rabeprazole and  esomoprazole. 
Cristina Iuga, et al., (2008) validated a HPLC-UV method for analysis of 
omeprazole in presence of its metabolites in human plasma.  Estimation of omeprazole in 
presence of its two main metabolites, hydroxyomeprazole and omeprazole sulfone in 
plasma were carried out. 
Syed AA, et al., (2008) developed a spectrophotometric method for the 
determination of certain proton pump inhibitors belonging to the benzimidazole class of 
compounds. The method is based on the reaction of omeprazole, lansoprazole, 
pantoprazole, rabeprazole and esomeprazole with iron (III) and subsequent reaction with 
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ferricyanide under neutral condition which led to a prussian blue product with maximum 
absorption at 720-730 nm.   
 
Ashraf Mahmoud, M., et al., (2009) has carried out new sensitive kinetic 
spectrophotometric method for the determination of omeprazole in dosage forms. The 
methods were based on the formation of charge-transfer complexes with both iodine and 
2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ). The formed complexes and the site 
of interaction were examined by computational modeling, UV/VIS, IR, and NMR 
spectroscopy. 
 
Amol Bhandage, et al., (2009) performed an extractive spectrophotometric 
determination of omeprazole in pharmaceutical preparations. The extractive 
spectrophotometric determination of omeprazole was developed using acidic dyes 
bromophenol blue and orange- G as ion pairing agents in aqueous medium (pH 7.0 and 
6.0 respectively). The ion-pair chromogen formed was extracted with chloroform, which 
was measured quantitative at 408nm and 508nm respectively.  
 
Syed Shakeel Ahmed, et al., performed three new visible spectrophotometric 
methods for the estimation of losartan potassium and omeprazole in single component 
pharmaceutical formulations. The methods were based on the formation of ion-pair 
complexes of the drug with dye Bromocresol purple(BCP) and Bromophenol blue(BPB), 
in acidic buffer solutions followed by their extraction in chloroform. 
 
Kothapalli, L.P., et al., (2010) developed a simultaneous spectrophotometric 
estimations of drotaverine hydrochloride and omeprazole. The absorbances of the 
standard solutions were taken at two wavelengths 229.5nm (λmax of drotaverine) and 
302nm (λmax of omeprazole) in methanol. 
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CINITAPRIDE HYDROGEN TARTARATE 
Alarcon de Lastra, C., et al., (1998) studied the effects of cinitapride on gastric 
ulceration and secretion in rats. The study demonstrated a gastro protective nature of 
cinitapride not only through reduction of neutrophil toxicity but by an increased 
synthesis of free radical scavenging enzymes glutathione peroxidase. Further it showed 
seratonergic dependent mechanisms are also involved by 5-HT2 blockade and 5-HT1 
receptor activation. 
Marta Robert, et al., (2007) studied that the prokinetic cinitapride has no 
clinically relevant pharmacokinetic interaction and effect on QT, during coadministration 
with ketoconazole. The safety and tolerability of the study treatments were also 
evaluated. The study showed that cinitapride, either given alone or after coadministration 
with ketoconazole 200 mg b.i.d., had no effect on cardiac repolarization as measured by 
changes in the heart rate-corrected QT interval on the surface electrocardiogram. 
Matias Manzotti, E., et al., (2007) determined the utility of prokinetic drugs 
(cinitapride, cisapride) in improving symptoms and endoscopic lesions in patients with 
GERD esophagitis.  
Helena Marquez, et al., (2011) developed a UHPLC method for the assessment 
of the metabolic profile of cinitapride. Metabolites were generated from the incubation of 
cinitapride with human liver microsomes. Cinitapride and its metabolites were separated 
by reversed-phase mode using a formate aqueous solution (pH 6.5) and acetonitrile as 
the components of the mobile phase Figures of merit were evaluated with cinitapride 
standards and incubated samples. Limits of detection are about 0.03μmol/L, and 
repeatabilities were better than 0.06% for retention times and better than 3.5% for 
concentrations. The method was applied to characterize the in vitro cinitapride 
metabolism with human liver microsomes. 
16 
 
 González Marti, I., et al., (1998) determined cinitapride by differential pulse 
polarography and adsorptive stripping voltammetry (ASV) in Britton–Robinson buffer, 
with 3s detection limits of 1.3×10−8  and 8.4×10−10  M, respectively. ASV was applied 
for the determination of  cinitapride  in  urine samples with an accumulation time of 65s. 
A 3s detection limit was found to be 1.8×10−7 M with RSD of  1% was  determined. 
Shikha Roy, M.N., et al., (2008) determined free levels of cinitapride in human 
plasma by liquid chromatography- tandem mass spectrometry.  Risperidone was used as 
the internal standard. The method was developed by extracting the sample and analyzed 
by high performance liquid chromatography coupled to electrospray tandem mass 
spectrometry API-4000 (LC-MS/MS). The method allowed an appropriate 
characterization of the pharmacokinetic profile of cinitapride at the therapeutic dose. 
Thangabalan, B., et al., (2010) validated extractive spectrophotometric 
estimation of cinitapride in pure and its solid dosage form. These  methods  are  based  
on  the  formation  of  chloroform  soluble  ion-association  complexes  of  cinitapride  
with bromocresol green (BCG) and with bromothymol blue (BTB) in potassium 
hydrogen phthalate buffer pH - 4.0 with absorption maximum at about 414 nm and 416 
nm for BCG and BTB respectively. 
Roy, S.M.N., et al., (2010) developed RP-HPLC method for the determination of 
cinitapride. The drug was subjected to all stress conditions such as reduction, oxidation 
acidic and alkaline medium. Acetonitrile and phosphate buffer, pH 6.7 in the ratio (70:30 
v/v) was used as the mobile phase and cinitapride detected at 260nm. Glimepride was 
used as internal standard. The drug was found to degrade extensively under reduction 
conditions and stable when subjected to thermal stress.  
Syeda Humaira, et al., (2010) developed colorimetric method for the 
determination of cinitapride hydrogen tartarate in drug formulations. Six simple and 
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sensitive spectrophotometric methods (A, B, C, D, E and F) have been developed for the 
quantitative estimation of cinitapride in bulk drug and pharmaceutical dosage forms. 
Method A and B is based on the oxidation followed by coupling of cinitapride with 1, 10 
phenanthroline and 2, 2’ bipyridyl in presence of ferric chloride to form orange‐red 
colored chromogen respectively. The other methods are based on the diazotization of 
cinitapride with nitrous acid followed by its coupling in situ with N‐ (1‐naphthyl) 
ethylenediamine dihydrochloride to form pinkish purple colored chromogen(C), with 
phloroglucinol to form orange colored chromogen (D), with diphenylamine to form pink 
colored chromogen (E) and with chromo tropic acid to form orange colored chromogen 
(F) respectively 
Syeda Humaira, et al., (2011) developed a validated RP-HPLC method to 
determine cinitapride hydrogen tartarate in solid oral dosage forms. Gradient elution 
technique with mobile phase consisting of 0.1% formic acid in water and acetonitrile and 
by UV detection at 268nm was utilized. The developed method was validated for 
precision which includes system precision and method precision, accuracy and linearity 
studies in the concentration range of 5-100 μg/mL with correlation coefficient of 0.9987. 
The accuracy (recovery) was found to be between 97.32 and 100.82%.  
Thangabalan, B., et al., (2011) analysed spectrophotometrically the amount of 
cinitapride in tablet dosage form using 2.0 M sodium benzoate solution as the 
hydrotropic solubilizing agent. Cinitapride is extracted from the dosage form thus 
precluding the use of costlier organic solvents. Cinitapride showed λ max at 395 nm and 
the Beer’s concentration was found to be 10-80µg/mL. The results were validated 
statistically and by recovery studies. 
Patel, G.H., et al., (2011) developed a validated method for the simultaneous 
determination of cinitapride and pantoprazole in capsule dosage form. They used. 
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aluminium plates precoated with silica gel 60 F254 as the stationary phase; ethylacetate: 
methanol (9: 1v/v) as the mobile phase and the  separated zones were densitometrically 
analysed at 278 nm. They have reported that two drugs were satisfactorily resolved with 
Rf values 0.43±0.00 and 0.62±0.01 for cinitapride and pantoprazole respectively.  
Accuracy and precision of the method was reported as per ICH guidelines. 
 
Ch Suresh, V., et al., (2011) developed a new visible spectrophotometric method 
for the determination of cinitapride in pharmaceutical dosage forms. They developed 
three methods involving charge transfer complex with chloranilic acid, oxidative 
coupling with MBTH and oxidation followed by complex formation with 1, 10 
Phenanthroline in the ferric chloride. The complexes were found to show λ max at 550, 
420, and 510nm respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Drug Profile  
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DRUG PROFILE 
 
OMEPRAZOLE 
Chemically omeprazole is a substituted 5-methoxy-2-[(4-methoxy-3, 5-dimethyl) 
sulfinyl] benzimidazole, a compound that inhibits gastric acid secretion. (IP, 1996; USP, 
2000)  
Empirical formula : C17H19N3O3S 
Molecular weight : 345.42 
Structure : 
H3CO
N
N
H
S
O
N
CH3 CH3
OCH3  
IUPAC name: 6-methoxy-2-{[(4-methoxy-3, 5-dimethylpyridin-2-yl) methane] 
sulfinyl}-1H-1, 3-benzodiazole 
Description: Omeprazole is a white to off-white crystalline powder that melts with 
decomposition at about 155°C. 
Solubility:  It is a weak base, freely soluble in ethanol and methanol, slightly soluble in 
acetone and isopropanol, and very slightly soluble in water. 
Stability:  The stability of omeprazole is a function of pH; it is rapidly degraded in acid 
media, but has acceptable stability under alkaline conditions. 
Mechanism of Action: Omeprazole is a proton pump inhibitor that suppresses gastric 
acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. By 
acting specifically on the proton pump, omeprazole blocks the final step in acid 
production, thus reducing gastric acidity. 
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Indications: For the treatment of gastroesophageal reflux disease (GERD), peptic ulcer 
disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID 
use.  It is also used to promote healing of erosive esophagitis (damage to your esophagus 
caused by stomach acid) 
Drug interactions: Alprazolam, atazanavir, chlordiazepoxide, cilostazol, clonazepam, 
clorazepate, indinavir, itraconazole, phenytoin, clopidogrel etc.,  
Food interactions: Avoid alcohol and take the drug 30-60 minutes before meals. 
Storage: Store omeprazole capsules in a tight container protected from light and 
moisture. Store between 15°C and 30°C (59°F and 86°F). Omeprazole pellets found in 
the capsules are fragile and should not be crushed. 
Contraindications: Omeprazole may cause a serious type of allergic reaction when used 
in patients with conditions treated with antibiotics.  Omeprazole delayed-release capsules 
are contraindicated in patients with known hypersensitivity to any component of the 
formulation. Hypersensitivity reactions may include anaphylactic shock, angioedema, 
bronchospasm, interstitial nephritis, and urticaria.  
Toxicity: Symptoms of overdose include confusion, drowsiness, blurred vision, 
tachycardia, nausea, diaphoresis, flushing, headache, and dry mouth. Omeprazole is 
considered a pregnancy Category C medication. This means omeprazole may not be safe 
for use during pregnancy 
Brand names:  Prilosec, Omez, Zegerid, Losec etc., 
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CINITAPRIDE (O’ Neil MJ., 2007;  S. C. Sweetman 2002 ) 
 Cinitapride is available in the form of Cinitapride hydrogen tartrate which 
is a new gastroprokinetic agent. It is a substituted benzamide with 5-HT receptor 
antagonist and agonist activity. It is chemically described as 4-Amino-N-[1-(3-
cyclohexen-1-ylmethyl)-4-piperidinyl]-2-ethoxy-5-nitrobenzamide hydrogen L-(+)-
tartrate.   
Empirical formula:    C25H36N40O10 
Molecular weight:     552.58. 
 
Structure   
 
 
Description: The tartarate salt of cinitapride is almost lemon yellow crystalline powder. 
It is freely soluble in methanol, soluble in water, ethanol, partially soluble in acetone, 
insoluble in carbon tetra chloride, chloroform.  
Solubility:  Cinitaprde hydrogen tartarate is freely soluble in methanol, ethanol, 
acetonitrile; soluble in water, 0.1N hydrochloric acid and practically insoluble in 
chloroform, acetone, ether and precipitates in 0.1N sodium hydroxide. 
Mechanism of Action: Cinitapride is a substituted benzamide gastroenteric prokinetic 
agent acting via complex, but synergistic effects on serotonergic 5-HT2 (inhibition) and 
5-HT4 (stimulation) receptor and dopaminergic D2 (inhibition) receptors in the neuronal 
synapses of the myenteric plexus. 
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Indications and Usage: Cinitapride is indicated for the treatment of gastrointestinal 
disorders associated with motility disturbances such as gastroesophageal reflux disease, 
non-ulcer dyspepsia and delayed gastric emptying. 
 
Dosage and Administration: The usual daily dosage for adults is 1mg of Cinitapride 
orally thrice a day 15 minutes before meals. The dose may be reduced, if required, 
depending on the patient’s age and symptoms at the discretion of the physician. 
 
Contraindications: Cinitapride is contraindicated in patients with known 
hypersensitivity to Cinitapride or any of the other constituents of the formulation. 
 
Drug Interactions: Anticholinergic agents like atropine, Scopolamine etc, may reduce 
the action of cinitapride. Cinitapride can enhance the effect of medicines that are used for 
the treatment of illnesses of the nervous system and for insomnia. Cinitapride can also 
alter the absorption of some medicines e.g. digoxin as it simulates gastric emptying. 
 
Undesirable Effects: Cinitapride has usually been very well tolerated with the most 
common adverse events in clinical trials being drowsiness and diarrhea. Extrapyramidal 
effects (involuntary muscular movements of the head, neck and tongue) have been 
reported occasionally. Very rarely, cutaneous reactions like eruptions, itching or 
angioedema and gynaecomastia have been reported. 
 
Overdosage: There have as yet been no reports of overdose in humans. The symptoms of 
overdose include drowsiness, confusion and extrapyramidal effects. Cinitapride hydrogen 
tartrate does not cause QT prolongation. In case of excessive overdosage, the usual 
measures of gastric lavage and symptomatic therapy should be applied. The 
extrapyramidal effects should be treated with antiparkinsonians, anticholinergics or 
antihistaminics with anticholinergic properties. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aim and Objective 
of the work 
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AIM AND OBJECTIVE OF THE WORK 
 
Analysis of drugs plays a major role in the development, manufacture and 
therapeutic use of drug. Quantitative analysis of raw materials and the final product is 
necessary to ensure that they meet certain specifications and contains the labeled amount 
of each component in the final product. 
Standard analytical procedures for newly designed and synthesized drugs are not 
available in any of the pharmacopoeias. So it becomes necessary to develop newer, 
accurate, specific, simple, easy to perform, reliable and economical analytical techniques 
for the estimation of the new drugs. 
The aim of the study is to develop various methods for the estimation of 
omeprazole and cinitapride combination in bulk and capsule dosage forms. 
Omeprazole is official in Indian Pharmacopoeia – 2010 and Cinitapride, a newer drug 
which was launched in 2007 is not official in any of the pharmacopoeias. It has been 
recently added in drug bank in 2012.  The combination of the two drugs has been 
launched in 2011. A review of literature revealed that no method has been developed for 
the determination of omeprazole (OME) and cinitapride (CNP) in combined tablet 
dosage form but several methods have been reported for the estimation of omeprazole 
and cinitapride individually and in combination with other drugs. There is no evidence 
for the estimation of OME and CNP by UV-Visible spectrophotometry and RP-HPLC 
methods in bulk and in combined tablet dosage form. So an attempt has been made to 
develop simple easy to perform, accurate, cost effective and rapid 
spectrophotometric methods for the estimation of OME and CNP in bulk and 
combined oral dosage form and also to validate the developed methods. 
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The objective of the present work is to develop and validate various methods for the 
estimation of the newer combination which includes: 
 UV Spectroscopy 
 Standard absorbance method 
 Area Under the Curve 
 First Derivative spectroscopy 
 Second Derivative spectroscopy 
 Visible Spectroscopy 
Colorimetry (Diazotisation followed by coupling for CNP) 
Colorimetry (Redox method for OME) 
 Reverse Phase High Performance Liquid Chromatographic method. 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Materials and 
Methods 
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MATERIALS AND METHODS 
MATERIALS 
Drug Samples 
Omeprazole enteric coated granules were obtained from Tablets India Private 
Limited, Chennai, TN (India) and Cinitapride hydrogen tartarate was obtained as a gift 
sample from M/S Zydus Cadila, Ankleshwar, Gujarat (India). The combined capsule 
dosage form was acquired from the local market. The capsule contained enteric coated 
granules of omeprazole equivalent to 20 mg of omeprazole and extended release tablet of 
cinitapride hydrogen tartarate equivalent to 3 mg of cinitapride. 
 
Reagents and Chemicals 
All chemicals and reagents used in the study were of analytical grade and 
procured from Merck India Ltd.  
 
Instrument Employed 
Shimadzu UV-Visible spectrophotometer, Model 1650PC  
 
METHOD 
ULTRA VIOLET SPECTROSCOPIC METHOD (Sharma, 1994)  
Most organic compounds absorb UV or Visible light making them susceptible for 
quantification using spectrophotometers. The technique of UV spectrophotometry is the 
most frequently employed in pharmaceutical analysis which involves the measurement 
of the amount of ultraviolet (200-400nm) or visible (380-800nm) radiation absorbed by a 
substance in solution. Absorption of light in both the UV and visible regions of the 
electromagnetic spectrum occurs when the energy of the light matches the requirement to 
induce an electronic transition in the analyte. The use of UV for quantitative analysis 
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employs the method of comparing the absorbance of standards and samples at a selected 
wavelength (Metreyi, 2008). The analysis of mixtures of two or more components is 
facilitated by measuring the absorbance. Other applications include measurement of 
absorption of complexes to establish their composition.  
 
Criteria for quantification of UV-visible spectroscopy 
 Molar absorptivity of the analyte.  
 Conformity to Beer- Lamberts’ Law. 
 Degree of selectivity and specificity. 
 
Establishment of various parameters 
 Absorption maximum 
 Beer’s concentration 
 Calibration graph 
 Estimation of analyte in dosage form 
 Recovery studies 
 
Selection of Solvent (Chatwal and Anand, 2000) 
 The drugs were found to be soluble in methanol. Since both the drugs OME and 
CNP were found to be freely soluble in methanol it was selected for the studies on OME 
and CNP by UV spectroscopy  
 
Preparation of the Standard Stock Solution 
 A standard stock solution of the analyte OME and CNP were prepared by 
dissolving an aliquot quantity of drug in methanol in two separate 100mL standard flask 
and made up to the volume with methanol to produce a concentration of 100µg/mL. 
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Preparation of Sample Solution 
The capsule dosage form contains CNP as extended release tablet and OME as 
enteric coated granules. Thus both the components were analyzed as separate entities. 
 
Selection of Absorption Maxima  
The standard stock solutions of both OME and CNP were appropriately diluted 
with methanol to obtain a concentration of 10µg/mL. These solutions were scanned in 
ultra violet region (200-350nm) using methanol as blank. It was found that OME 
exhibited an intense maximum absorption at 301nm (Fig-1).  
 
Fig 1: Absorption spectra of OME 
Similarly, CNP exhibited an intense maximum absorption at 262nm (Fig-2). 
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Fig 2: Absorption spectra of CNP 
 
Establishment of Beer’s Concentration and Linearity 
Omeprazole 
The stock solution (1000 µg/ mL) of OME were suitably diluted with methanol to 
obtain a concentration ranging from 4-20 µg/ mL.  The final dilutions were scanned in 
ultraviolet region against methanol as blank. The λ max was found to be stable at 301 nm 
hence the absorbance of the dilutions were measured at the selected λ max, 301 nm.  
 
Cinitapride 
The stock solution (1000 µg/ mL) of CNP was suitably diluted with methanol to 
obtain concentration ranging 4-20 µg/ mL. The final dilutions were scanned in ultraviolet 
region against methanol as blank. The λ max was found to be stable at 262nm hence the 
absorbance of the dilutions were measured at the selected λ max, 262nm.  
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Analysis of Formulation 
The capsule dosage form contained OME as enteric coated granules and CNP as 
extended release tablet. Thus both the components were analyzed as separate entities. 
The amount of OME and CNP was calculated using the formula  
 
 
 
 
 
 
Recovery studies 
To study the accuracy, precision and reproducibility of the proposed method, the 
recovery studies were carried out on spiked samples by adding predetermined amount of 
standard drugs to the respective sample. About 20, 40 and 100% of standard drugs were 
added to the sample solutions and the absorbance was measured against methanol blank. 
The percentage recovered was calculated. The recovery studies were performed at three 
levels for all the four methods to confirm the accuracy of the above said methods. 
  
 
The percentage purity was calculated using the formula. 
 
 
 
 
 
 
Amount present 
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METHOD A:   STANDARD ABSORBANCE METHOD 
OMEPRAZOLE 
Enteric coated granules of twenty capsules of OME was accurately weighed and 
crushed to fine powder. Powder equivalent to 50mg of OME was weighed in a 100mL 
volumetric flask, shaken vigorously with sufficient amount of methanol for half an hour 
and finally made up to volume with methanol. The resulting solution was filtered 
through Whatmann filter paper (No.41). The first few mL of the filtrate was discarded 
and appropriate dilutions were made with methanol from stock solutions to get a 
concentration of 10µg/mL of OME. The absorption maximum of the resulting solution 
was measured at 301 nm against methanol blank (Fig-3). The values are given in the 
Table-1. 
 
 
Fig 3: Overlain spectra of OME 
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   Table 1: Absorbance of OME at 301nm 
Sl. No. Concentration (in µg/mL) Absorbance* 
1 4 0.217 
2 8 0.434 
3 10 0.542 
4 12 0.651 
5 16 0.868 
6 20 1.082 
    
*Each value is the mean of three readings 
 
Calibration graph 
A graph of absorbance versus concentration was plotted. From the graph Beer’s 
law concentration for the analyte was found to be between 4-20μg/mL for OME (Fig-4) 
 
Fig 4: Calibration chart of OME at 301nm 
 
Analysis of Sample 
The amount of OME was calculated using the formula mentioned above and the 
results are tabulated in Table-2. 
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 Table 2: Results of Assay of OME using Standard Absorbance method 
 
Sl. 
No. 
Label 
claim 
Amount present 
(in mg) ± SD* RSD % Purity ± SD % RSD 
1. 
20mg 
20.34 ± 0.00006 0.0030 101.70 ± 0.3099 0.0030 
2. 20.16 ± 0.00003 0.0019 100.80 ± 0.1937 0.0019 
3. 20.37 ± 0.00018 0.0092 101.89 ± 0.9400 0.0092 
   
 *Each value is the mean of three determinations. 
 
Recovery studies 
The percentage purity was calculated using the formula mentioned above and  the 
results are tabulated in Table-3. 
 
 Table 3: Results of Recovery Studies of OME using Standard Absorbance method 
Ex
pe
ct
ed
 
%
 R
ec
ov
er
y 
Amount of 
Drug Added 
in mg Total 
Amount 
Assayed 
(mg) * 
Amount 
Recovered 
(mg) 
Assessed 
% 
Recovery 
% Recovered  
± S.D 
% 
RSD 
Sa
m
pl
e 
St
an
da
rd
 
20% 
20mg 
4 24.19 4.03 20.16 100.80 ± 0.387 0.019 
40% 8 28.18 8.02 40.08 100.21 ± 0.774 0.019 
100% 20 40.12 19.96 99.78 99.78 ± 0.223 0.002 
     
*Each value is the mean of three determinations. 
 
Cinitapride 
Twenty tablets of CNP were accurately weighed and crushed to fine powder. 
Tablet powder equivalent to 10mg of the CNP was weighed in a 100 mL volumetric 
flask, shaken vigorously with sufficient amount of methanol for half an hour. Finally the 
solution was made up to volume with methanol. The solution was well shaken and 
filtered through Whatmann filter paper (No.41). The first few mL of the filtrate was 
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discarded and an aliquot quantity of the filtrate was diluted to obtain a final 
concentration of 10µg/mL of CNP. The absorbance of the resulting solution was 
measured at 262nm against methanol blank (Fig-5). The values are given in the Table-4. 
 
nm 
Fig 5: Overlain spectra of CNP 
 
                                Table 4: Absorbance of CNP at 262nm 
Sl. No. Concentration (in µg/mL) Absorbance* 
1 4 0.224 
2 8 0.449 
3 10 0.561 
4 12 0.672 
5 16 0.896 
6 20 1.121 
                       
*Each value is the mean of three readings 
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Calibration graph 
A graph of absorbance versus concentration was plotted. From the graph Beer’s 
law concentration for the analyte was found to be between 4-20μg/mL for CNP (Fig-6).  
 
 
 
Fig 6: Calibration chart of CNP at 262nm 
 
Analysis of Sample 
The amount of CNP was calculated using the formula mentioned above and the 
results are tabulated in Table-5. 
 
 
 Table 5: Results of Assay of CNP using Standard Absorbance method 
 
Sl. 
No. 
Label 
claim 
Amount present 
(in mg) ± SD* RSD % Purity ± SD % RSD 
1. 
3mg 
3.0  ± 0.000004 0.143 101.85 ± 0.145 0.00143 
2. 2.9  ± 0.000002 0.056 99.43 ± 0.056 0.00056 
3. 2.9  ± 0.000003 0.097 99.59 ± 0.097 0.00097 
   
 *Each value is the mean of three determinations. 
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Recovery studies 
The percentage purity was calculated using the formula mentioned above and  the 
results are tabulated in Table-6. 
 
Table 6: Results of Recovery Studies of CNP using Standard Absorbance method 
 
Ex
pe
ct
ed
 
%
 R
ec
ov
er
y 
Amount of 
drug added 
in mg Total 
Amount 
Assayed 
(mg) * 
Amount 
Recovered 
(mg) 
Assessed 
% Recovery 
% Recovered  
± S.D % RSD 
Sa
m
pl
e 
St
an
da
rd
 
20% 
3mg 
0.6 3.62 0.61 20.31 101.55  ±0.18 0.0089 
40% 1.2 4.23 1.22 40.71 101.78  ±0.45 0.0112 
100% 3.0 6.05 3.04 101.24 101.24  ±0.64 0.0063 
     
*Each value is the mean of three determinations. 
 
 
 
METHOD B:   AREA UNDER CURVE  
The AUC (area under curve) method (Mukesh, 2007) is applicable when there is 
no sharp peak or when broad spectra are obtained. It involves the calculation of 
integrated value of absorbance between the two selected wavelengths λ1 and λ2. The 
inbuilt software calculates the area bound by the curve and the horizontal axis. The 
horizontal axis is selected by entering the wavelength range over which the area has to be 
calculated. The wavelength range is selected on the basis of repeated observations so as 
to get the linearity between area under curve and concentration.  
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Establishment of various parameters 
 Area under curve 
 Linearity 
 Calibration chart 
 Recovery studies 
Area under curve 
The standard spectra obtained in the establishment of linearity and the sample 
spectra for both OME and CNP obtained in method A were used. The calibration graph 
was plotted against AUC and concentration and the linearity was established. The sample 
AUC was interpolated on the respective linearity chart of the AUC and the concentration 
was determined.   
 
Analysis of Sample 
The amount present per tablet was calculated by using the formula.  
 
 
 
Recovery studies 
The recovery studies were performed at three levels to confirm the accuracy of 
the above said methods.  
 
Omeprazole 
The AUC for OME were determined between 281 and 328.8nm for both standard 
and sample (Fig-7).  
Amount present =     
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Fig 7: AUC of OME between 281 and 328.8nm 
 
Linearity range 
The AUC obtained for different concentration of standard solution of OME are 
represented in Table-7. 
 
Table 7: AUC of OME between 281 and 328.8nm 
Sl. No. Concentration (in µg/mL) Area under curve* 
1 4 3.245 
2 8 6.520 
3 10 7.696 
4 12 9.751 
5 16 13.025 
6 20 16.230 
    
 *Each value is the mean of three readings 
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Calibration graph 
A graph of AUC against concentration was plotted. From the graph, it was found 
that the drug obeyed linearity in the range 4-20μg/mL for OME (Fig-8) 
 
 
Fig 8: Calibration curve of OME by AUC method 
 
Analysis of Sample 
The amount of OME was calculated using the formula mentioned above and the 
results are tabulated in Table-8. 
 
 Table 8: Results of Assay of OME using AUC 
 
Sl. No. Label claim Amount present (in mg) ± SD* RSD % Purity ± SD % RSD 
1. 
20mg 
20.16 ± 0.00017 0.0083 100.78 ± 0.8397 0.0083 
2. 20.31 ± 0.0001 0.0051 101.56 ± 0.5248 0.0051 
3. 20.19 ± 0.00013 0.0063 100.96 ± 0.6413 0.0063 
    
 *Each value is the mean of three readings 
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Recovery studies 
The percentage purity was calculated and  the results are tabulated in Table-9. 
 
Table 9: Results of Recovery Studies of OME using AUC 
 
Ex
pe
ct
ed
 
%
 R
ec
ov
er
y 
Amount of 
drug added 
in mg Total 
Amount 
Assayed 
(mg) * 
Amount 
Recovered 
(mg) 
Assessed 
% Recovery 
% Recovered  
± S.D 
% 
RSD 
Sa
m
pl
e 
St
an
da
rd
 
20% 
20mg 
4 24.37 4.06 20.31 101.56 ± 0.209 0.010 
40% 8 28.37 8.05 40.28 100.74 ± 0.801 0.019 
100% 20 40.28 19.96 99.85 99.85 ± 1.210 0.012 
     
*Each value is the mean of three determinations. 
 
Cinitapride 
Similarly for CNP, the AUC between 239.8 and 296.4nm for both standard and 
sample (Fig-9) were determined. 
 
Fig 9: AUC of CNP between 239.8 and 296.4nm 
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Linearity range 
The AUC obtained for different concentration of standard solution of CNP are 
represented in Table-10. 
Table 10: AUC of CNP between 239.8 and 296.4nm 
Sl. No. Concentration (in µg/mL) Area under curve* 
1 4 3.696 
2 8 7.314 
3 10 8.699 
4 12 10.559 
5 16 13.967 
6 20 17.894 
    
 *Each value is the mean of three readings 
Calibration graph 
A graph of AUC against concentration was plotted. From the graph, it was found 
that the drug obeyed linearity in the range 4-20μg/mL for CNP (Fig-10) 
 
Fig 10: Calibration curve of CNP by AUC method 
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Analysis of Sample 
The amount of CNP was calculated using the formula mentioned above and the 
results are tabulated in Table-11. 
 
Table 11: Results of Assay of CNP using AUC 
 
Sl. 
No. 
Label 
claim 
Amount present 
(in mg) ± SD* RSD % Purity ± SD % RSD 
1. 
3mg 
3.04  ± 0.000028 0.0093 101.57 ± 0.945 0.0093 
2. 3.02  ± 0.000019 0.0062 100.68 ± 0.630 0.0062 
3. 3.02  ± 0.000019 0.0062 100.68 ± 0.630 0.0062 
 
*Each value is the mean of three determinations. 
 
 
Recovery studies 
The percentage purity was calculated and  the results are tabulated in Table-12. 
 
Table 12: Results of Recovery Studies of CNP using AUC 
 
Ex
pe
ct
ed
 
 %
 R
ec
ov
er
y 
Amount of 
Drug Added 
in mg Total 
Amount 
Assayed 
(mg)* 
Amount 
Recovered 
(mg) 
Assessed 
% Recovery 
% Recovered ± 
S.D 
% 
RSD 
Sa
m
pl
e 
St
an
da
rd
 
20% 
3mg 
0.6 3.67 0.60 20.13 100.66 ± 0.59 0.029 
40% 1.2 4.27 1.21 40.18 100.45 ± 0.59 0.014 
100% 3.0 6.10 3.03 100.95 100.95 ± 0.29 0.002 
 
*Each value is the mean of three determinations. 
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METHOD C: FIRST DERIVATIVE SPECTROSCOPY (A.H. Beckett, 2007) 
Derivative spectrophotometry involves the conversion of normal spectrum to its 
first, second or higher derivative spectrum. In derivative spectroscopy, the ability to 
detect and to measure minor spectral features is considerably enhanced. It can be used in 
quantitative analysis to measure the concentration of an analyte whose peak is obscured 
by a larger overlapping peak. It is useful in eliminating matrix interference in a assay of 
many medicinal substances. Derivative spectrum is done by wavelength modulation with 
dual wavelength photometers and microprocessor controlled digital photometer.  
Normal spectrum is a zero order spectrum. The first derivative (D1) spectrum is 
the plot of the rate of change of absorbance with wavelength against wavelength i.e., the 
plot of the slope of the fundamental spectrum against wavelength or dA/dλ vs.  λ. It is 
characterized by a maximum, minimum and cross over point at the λmax of the absorption 
band (IP, 1996). 
Advantages: 
a. Accurate determination of λmax is possible. 
b. Absorption bands can be recognized when there are two or more absorption 
bands overlapping at the same or slightly different wavelength. 
c. Increased resolution permits the selective determination of certain absorbing 
substances. 
 
Omeprazole 
OME showed zero cross over point at 301nm (Fig-11).  The amplitude of the 
positive maxima of OME was measured and plotted against concentration Table-13 to 
determine the linearity. The sample amplitudes were interpolated on the respective 
linearity chart of the derivative spectra and the concentration was determined.  
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nm 
 
Fig 11: Overlain spectra of first derivative of Omeprazole 
 
 
 
  Table 13: Amplitude of positive maxima and concentrations 
                                 (First Derivative Spectroscopy) 
Sl. No. Concentration (in µg/mL) 
First derivative 
Amplitude* 
1 4 7 
2 8 1.4 
3 10 1.7 
4 12 2.2 
5 16 2.9 
6 20 3.6 
        
       *Each value is the mean of three determinations. 
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Calibration graph  
A graph of amplitude against concentration was plotted. From the graph, it was 
found that the drug obeyed linearity in the range 4-20μg/mL (Fig-12). 
 
Fig 12: Calibration chart of OME by First derivative spectroscopy 
Analysis of Sample 
The amount of OME was calculated using the formula mentioned above and the 
results are tabulated in Table-14. 
 
Table 14: Results of Assay of OME using First derivative spectroscopy 
 
Sl. No. Label claim Amount present (in mg) ± SD* RSD % Purity ± SD % RSD 
1. 
20mg 
20.29 ± 0.00019 0.0095 101.47 ± 0.9696 0.0095 
2. 20.14 ± 0.00024 0.0120 100.70 ± 1.2121 0.0120 
3. 20.31 ± 0.00021 0.0103 101.56 ± 1.0400 0.0103 
    
*Each value is the mean of three determinations 
 
Recovery studies 
The percentage purity was calculated and  the results are tabulated in Table-15. 
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Table 15: Results of Recovery Studies of OME using First Derivative method 
Ex
pe
ct
ed
 
 %
 R
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y 
Amount of 
Drug Added 
in mg Total 
Amount 
Assayed 
(mg)* 
Amount 
Recovered 
(mg) 
Assessed 
% Recovery 
% Recovered 
 ± S.D 
% 
RSD 
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m
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e 
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20% 
20mg 
4 23.86 4.06 20.31 101.56 ± 0.209 0.010 
40% 8 27.79 7.99 39.94 99.84 ± 0.121 0.003 
100% 20 39.77 19.97 99.85 99.85 ± 1.210 0.012 
 
*Each value is the mean of three determinations. 
Cinitapride 
CNP showed zero cross over point at 262nm (Fig-13).  The amplitude of the 
positive maxima of CNP was measured and plotted against concentration Table-16 to 
determine the linearity. The sample amplitudes were interpolated on the respective 
linearity chart of the derivative spectra and the concentration was determined. 
 
Fig 13: Overlain spectra of first derivative of Cinitapride 
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Table 16:   Amplitude of positive maxima and concentrations 
                                      (First Derivative Spectroscopy) 
Sl. No. Concentration (in µg/mL) 
First derivative 
Amplitude* 
1 4 1.5 
2 8 3.0 
3 10 3.6 
4 12 4.2 
5 16 5.6 
6 20 7.0 
    
   *Each value is the mean of three determinations. 
Calibration graph 
A graph of amplitude against concentration was plotted. From the graph, it was 
found that the drug obeyed linearity in the range 4-20μg/mL (Fig-14). 
 
 
 
Fig 14: Calibration chart of CNP by First derivative spectroscopy 
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Analysis of Sample 
The amount of CNP was calculated using the formula mentioned above and the 
results are tabulated in Table-17. 
 
Table 17: Results of Assay of CNP using First derivative spectroscopy 
Sl. 
No. 
Label 
claim 
Amount present 
(in mg) ± SD* RSD % Purity ± SD % RSD 
1. 
3mg 
3.0  ± 0.000014 0.0046 101.24 ± 0.472 0.0046 
2. 2.9  ± 0.000009 0.0031 99.80 ± 0.315 0.0031 
3. 2.9  ± 0.000014 0.0047 99.91 ± 0.472 0.00473 
  
 *Each value is the mean of three determinations 
 
Recovery studies 
 The percentage purity was calculated and  the results are tabulated in Table-18. 
 
Table 18: Results of Recovery Studies of CNP using First Derivative method 
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20% 
3mg 
0.6 3.63 0.59 19.80 98.99 ± 0.29 0.0149 
40% 1.2 4.25 1.22 40.68 101.70 ± 0.51 0.0125 
100% 3.0 6.06 3.03 101.04 101.04 ± 1.06 0.0105 
 
*Each value is the mean of three determinations. 
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METHOD D: SECOND DERIVATIVE SPECTROSCOPY 
The second derivative (D2) spectrum is the plot of the curvature of the D0 
spectrum or a plot of d2A/ dλ2 against λ (IP, 1996). The zero order spectra obtained in the 
linearity characterization of method A were derivatized to get second order spectra. 
OME showed negative maxima at 301(Fig-15) and CNP at 262nm (Fig-17). The 
amplitude of the negative maxima corresponding to λmax of fundamental spectrum were 
measured and plotted against concentration to determine the linearity. The sample 
amplitudes were interpolated on the respective linearity chart of the derivative spectra 
and the concentration was determined.  
 
Omeprazole 
The amplitude of the negative peak maximum was measured in mm at 301nm for 
OME are presented in Table-19. 
 
Fig 15: Overlain spectra of second derivative of Omeprazole 
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Table 19:   Amplitude of negative maxima and concentrations 
(Second Derivative Spectroscopy) 
 
Sl. No. Concentration (in µg/mL) 
Second derivative 
Amplitude* 
1 0 0 
2 4 1.2 
3 8 2.5 
4 10 3.0 
5 12 3.8 
6 16 5.1 
7 20 6.4 
     
*Each value is the mean of three readings 
 
Calibration graph 
A graph of amplitude of the negative peak maximum against concentration was 
plotted. From the graph, it was found that the drug OME obeyed linearity in the range of 
4-20μg/mL (Fig-16). 
 
Fig 16: Calibration chart of OME by Second derivative spectroscopy 
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Analysis of Sample 
The amount of OME was calculated using the formula mentioned above and the 
results are tabulated in Table-20. 
 Table 20: Results of Assay of OME by Second derivative spectroscopy 
 
Sl. 
No. 
Label 
claim 
Amount present 
(in mg) ± SD* RSD % Purity ± SD % RSD 
1. 
20mg 
20.03 ± 0.00019 0.0095 101.47 ± 0.9696 0.0095 
2. 19.96 ± 0.00012 0.0060 99.85 ± 0.6060 0.0060 
3. 20.01 ± 0.00021 0.0104 100.28 ± 1.0490 0.0104 
 
       *Each value is the mean of three readings 
 
Recovery studies 
The percentage purity was calculated and  the results are tabulated in Table-21. 
Table 21: Results of Recovery Studies of OME by Second Derivative method 
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20% 
20mg 
4 24.60 4.03 20.14 100.74 ± 0.2424 0.012 
40% 8 28.64 8.07 40.37 100.91 ± 0.2099 0.005 
100% 20 40.45 19.88 99.41 99.41 ± 1.2100 0.012 
 
*Each value is the mean of three readings 
Cinitapride 
The amplitude of the negative peak maximum was measured in mm at 262nm for 
CNP are presented in Table-22. 
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Table 22:   Amplitude of negative maxima and concentrations 
(Second Derivative Spectroscopy) 
Sl. No. Concentration (in µg/mL) 
Second derivative 
Amplitude* 
1 4 2 
2 8 4 
3 10 4.9 
4 12 5.9 
5 16 7.7 
6 20 9.6 
 
     *Each value is the mean of three readings 
 
The overlain spectra of CNP by Second order derivative is shown in Fig-17. 
 
 
nm 
Fig 17: Overlain spectra of second derivative of Cinitapride 
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Calibration graph 
A graph of amplitude of the negative peak maximum against concentration was 
plotted.  From  the  graph,  it  was  found  that  the  drug CNP  obeyed  linearity  in  the  
range 4-20μg/mL (Fig-18). 
 
Fig 18: Calibration chart of CNP by Second derivative spectroscopy 
 
Analysis of Sample 
The amount of OME was calculated using the formula mentioned above and the 
results are tabulated in Table-23. 
 
Table 23: Results of Assay of CNP by Second Derivative spectroscopy 
 
Sl. 
No. 
Label 
Claim 
Amount present 
(in mg) ± SD* RSD % Purity ± SD % RSD 
1. 
3mg 
3.05  ± 0.000014 0.0046 101.91 ± 0.472 0.0046 
2. 2.99  ± 0.000009 0.0031 99.80 ± 0.315 0.0031 
3. 2.99  ± 0.000014 0.0047 99.91 ± 0.472 0.0047 
 
 *Each value is the mean of three determinations. 
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Recovery studies 
The percentage purity was calculated and  the results are tabulated in Table-24. 
 
Table 24: Results of Recovery Studies of CNP by Second Derivative method 
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20% 
3mg 
0.6 3.61 0.58 19.59 97.94 ± 0.295 0.015 
40% 1.2 4.25 1.22 40.68 101.70 ± 0.511 0.012 
100% 3.0 6.06 3.03 101.04 101.04 ± 1.060 0.010 
 
*Each value is the mean of three determinations. 
 
II. VISIBLE SPECTROPHOTOMETRY  
Visible spectroscopy (Vogel, 1989) is the study of the interaction of radiation 
from the visible part 400-800nm of the electromagnetic spectrum with a chemical 
species. The use of visible spectroscopy for quantitative analysis employs the method of 
comparing the absorbance of reference standards and samples at a selected wavelength. 
Various colorimetric methods include oxidation or reduction, diazotization followed by 
coupling, complexing with metal ions, ion pair complexes with indicator dyes etc. 
Advantages of colorimetric procedures 
 A colorimetric method will often give more accurate results at low 
concentrations than the corresponding titrimetric or gravimetric procedure. 
 It may be simpler to carry out. 
 It may be frequently applied under conditions where no satisfactory 
gravimetric or titrimetric procedure exists. 
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The criteria for the selection of the procedure include 
 Specificity/Stability of the colour reaction 
 Proportionality between colour and concentration 
 Clarity of the solution 
 High sensitivity 
 Stability of absorbance with respect to time, variation of pH, ionic strength 
and temperature. 
 Degree of selectivity of reagents includes the effect of other species likely to 
be present. 
 Conformity to the Beer Lambert’s law and plot calibration data for the range 
of concentration measured. 
 
Colorimetric estimation of Cinitapride using Diazotisation Method 
The colorimetric estimation of CNP is based on the diazotization followed by 
complexation. Method A involves the complexation of diazotized CNP with ethyl aceto 
acetate (EAA). Method B with that of acetyl acetone (AAC).  
 
Preparation of reagents 
Sodium nitrite solution (2%): 2gms of sodium nitrite was dissolved in distilled water 
and made up to volume with the same. 
Hydrochloric acid 0.5 mol L-1:  42.5gms of concentrated hydrochloric acid was made up 
to 1000 mL in distilled water. 
Ethyl aceto acetate (EAA) (2%) solution: 2 mL of acetyl acetone was dissolved in 5mL 
of alcohol and the volume is made up to 100mL with distilled water.  
Acetyl acetone (AAC) (2%) solution: 2 mL of acetyl acetone was dissolved in 5mL of 
alcohol and the volume is made up to 100mLwith distilled water. 
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Sodium hydroxide 1 mol L-1: 4gms of sodium hydroxide was dissolved in distilled water 
and the made up to 100 mL with the same. 
Establishment of optimum levels of various parameters 
 Volume of reagent 
 Stability of color 
 Absorption maximum 
 Beer’s concentration 
 Calibration graph 
 Estimation of analyte in dosage form 
 
METHOD A:  Using EAA (Chand Pasha, et al., 2010) 
Preparation of Standard stock solution 
Accurately weighed quantity of standard CNP was dissolved in distilled water 
and the volume is made up to obtain a final concentration of 500 µg/mL which was used 
as the stock solution. 
Spectral characterization and Linearity Establishment 
Aliquots of standard stock solution were transferred to a series of 50mL 
volumetric flasks, add 2mL of 2% sodium nitrite solution and 2mL of 0.5M hydrochloric 
acid and maintained at a temperature of about 0-5° C for 5 minutes for completion of the 
diazotization reaction.  
A reddish orange coloured chromogen was formed by the addition of 2 % EAA 
followed by the addition of 1 mL of 1M sodium hydroxide to each of the reaction 
mixture. Finally the solutions were made up to volume with distilled water and shaken 
well. The absorbance of the reddish orange coloured chromogen was scanned between 
350-800nm against distilled water blank. The chromogen gave maximum absorbance at 
392.5 nm.  
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Determination of Absorption Maximum 
The estimation of CNP is based on the formation of a diazonium salt with sodium 
nitrite and hydrochloric acid (as the analyte possess primary aromatic group) and then 
coupling with EAA in an alkaline medium provided by the addition of sodium hydroxide 
solution to form a complex. The complex formed is reddish orange in colour for which 
the maximum absorbance was observed at 392.5nm 
Optimisation 
Diazotization and complexation reaction condition: 
The conditions for the diazotization (Shahar Yar M) are well established to be at 
0-5°C. An elevated temperature leads to incomplete diazotization and decomposition of 
diazotized compound (Jim Clark). The volume and strength of the sodium nitrite, 
hydrochloric acid and sodium hydroxide used were optimized. It was found that an 
increase or decrease from 1-2mL and 1-4% of sodium nitrite brought about no change in 
response or very less absorbance. 
 By trial and error it was established that 2mL each of 2% sodium nitrite solution, 
0.5M hydrochloric acid and 2% EAA were found to give good linear relationship 
between absorbance and concentration. 1mL of 1M sodium hydroxide was optimal to 
ensure complete complexation and good colour intensity. Any change in the volume or 
strength of the above reagents showed deviation from the linearity. 
 Finally the concentration of the analyte was also studied. Concentrations below 
10µgm and above 60µg/mL showed low colour intensity and deviation from the linearity 
respectively. Hence 10-60µg/mL of CNP obeyed Beer’s law and was selected for the 
study.  Cinitapride forms a diazonium salt on diazotization and the diazo complex CNP-
EAA was obtained on coupling with ethyl aceto acetate. The chromogen formed was 
orange red in colour. 
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Reaction Mechanism: 
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A graph was plotted using absorbance against concentration and linear regression 
analysis was applied to determine the linearity (Table-25). The overlain spectra of the 
EAA coupled with standard CNP for the linearity studies are shown in Fig-19.   
 
 
 
nm 
Fig 19: Absorption maxima of EAA coupled CNP complex at 392.5nm 
 
Table 25: Absorbance of CNP- EAA complex at 392.5 nm 
                                 
 
 
 
 
 
 
 
 
                           *Each value is the mean of three determinations 
 
Sl. No. Concentration (in µg/mL) Absorbance* 
1 10 0.222 
2 20 0.424 
3 30 0.644 
4 40 0.882 
5 50 1.064 
6 60 1.265 
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The correlation coefficient was found to be 0.999 as shown in Fig-20. 
 
Fig 20: Calibration chart of cinitapride 
 
Analysis of Formulation 
Twenty tablets of CNP from the capsules were accurately weighed and ground to 
fine powder. From this, tablet powder equivalent to 25 mg of CNP was accurately 
weighed and shaken well with distilled water for 20 minutes, made up to volume with 
distilled water to obtain a concentration of 250µg/mL. The solution was then filtered 
through Whatmann filter paper No.41. Discarded the first few mL of the filtrate and 6mL 
of the filtrate were transferred to a 50mL volumetric flask. The sample solution was 
diazotized, complexed with EAA and the absorbance was measured using the same 
procedure as that of standard CNP.  
The amount of drug present in each tablet was calculated by using the formula 
and the results are presented in Table-26. 
 
 
Amount present 
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      Table 26: Results of Assay of CNP using EAA 
 
Sl. 
No. 
Label 
Claim 
Amount present 
(in mg) ± SD* RSD % Purity ± SD RSD 
1. 
3 mg 
2.98  ± 0.000010 0.0034 99.17 ± 0.3373 0.0034 
2. 2.99  ± 0.000008 0.0026 99.54 ± 0.2654 0.0026 
3. 2.99  ± 0.000020 0.0068 99.17 ± 0.4720 0.0068 
            
*Each value is the mean of three determinations. 
 
Recovery studies 
To study the accuracy, precision and reproducibility of the proposed method, the 
recovery studies were carried out on spiked samples by adding predetermined amount of 
standard drugs to the respective sample. The percentage recovered was calculated and 
the results obtained are presented in Table-27. 
 
 
Table 27: Recovery studies of CNP using EAA 
     
*Each value is the mean of three determinations. 
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27 % 
3mg 
0.8 3.8 0.8 27.62 101.51 ± 0.590 0.0214 
50 % 1.5 4.44 1.50 48.91 98.15 ± 0.515 0.0105 
100 % 3.0 5.91 2.90 100.95 98.11± 0.389 0.0039 
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METHOD B: Using AAC 
 
Preparation of Standard stock solution 
Accurately weighed quantity of standard CNP was dissolved in distilled water 
and the volume is made up to obtain a final concentration of 1000 µg/mL which was 
used as the stock solution. 
 
Spectral characterization and Linearity Establishment 
From the stock solution 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 mL were transferred into six 
50mL volumetric flasks. To each of the volumetric flasks 2mL of 2% sodium nitrite 
solution and 2mL of 1M hydrochloric acid was added and maintained at a temperature of 
about 0-5° C for 5 minutes to carry out the diazotization. A reddish orange coloured 
chromogen was formed by the addition of 2 % AAC followed by the addition of 1mL of 
1M sodium hydroxide to each of the reaction mixture. Finally the solutions were made 
up to volume with distilled water and shaken well. The absorbance of the reddish orange 
coloured chromogen was scanned between 350-800nm against distilled water blank. The 
chromogen gave maximum absorbance at 399nm. 
 
Determination of Absorption Maximum 
The estimation of CNP is based on the formation of a diazonium salt with sodium 
nitrite and hydrochloric acid (as the analyte possess primary aromatic group) and then 
coupling with AAC in an alkaline medium provided by the addition of sodium hydroxide 
solution to form a complex. The complex formed is reddish orange in colour for which 
the maximum absorbance was observed at 399nm. 
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Reaction Mechanism: 
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Optimisation 
Diazotization and complexation reaction condition: 
The conditions for the diazotization are well established to be at 0-5°C. An 
increased temperature results in incomplete diazotization and decomposition of 
diazotized compound. The volume and strength of the sodium nitrite, hydrochloric acid 
and sodium hydroxide used were optimized. It was found that an increase or decrease 
from 1-2mL and 1-4% of sodium nitrite brought about no change in response or very less 
absorbance. By trial and error it was established that 2mL of 2% sodium nitrite solution, 
2mL of 2% AAC were found to give good linear relationship between absorbance and 
concentration. Any change in the volume or strength of AAC showed deviation from the 
linearity. It was observed that 1mL of 1M sodium hydroxide was optimal to ensure 
complete complexation and good colour intensity. Finally the concentration of the analyte 
was also studied. Lower the concentration (below 10µgm) lower was the colour intensity 
as a result the absorbance was very less and did not show much difference in the 
absorbance. Higher concentration (above 60µg/mL) showed deviation from the linearity. 
Thus 10-60µg/mL of CNP obeyed Beer’s law and was selected for the study.  
A graph was plotted using absorbance against concentration and linear regression 
analysis was applied to determine the linearity (Table-28).  
Table 28: Absorbance of CNP- AAC at 392.5 nm 
 
                                   
 
 
 
 
 
                              *Each value is the mean of three determinations 
 
Sl. No. Concentration (in µg/mL) Absorbance* 
1 10 0.172 
2 20 0.330 
3 30 0.494 
4 40 0.651 
5 50 0.776 
64 
 
The overlain spectra of the AAC coupled standard CNP for the linearity studies 
are shown in Fig-21. 
 
nm 
Fig 21: Absorption maxima of CNP coupled AAC complex at 392.5nm              
                         
The correlation coefficient was found to be 0.999 as shown in Fig-22. 
 
 
                              Fig 22: Calibration chart of cinitapride 
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Quantification of Formulation 
Twenty tablets of CNP from the capsules were accurately weighed and ground to 
fine powder. From this, tablet powder equivalent to 25 mg was accurately weighed and 
shaken well with water for 20 minutes, made up to volume with distilled water to obtain a 
concentration of 250µg/mL. The solution was then filtered through Whatmann filter paper 
No.41. Discarded first few mL of the filtrate, and 6 mL of the filtrate was transferred to a 
50 mL volumetric flask.  
The sample solution was diazotized, complexed with AAC and the absorbance was 
measured using the same procedure as that of standard CNP. The amount of drug present 
and percentage recovery were calculated and presented in Table-29 and 30 respectively 
Table 29: Results of Assay of CNP using AAC 
Sl. No. Label Claim 
Amount present 
(in mg) ± SD* RSD % Purity ± SD RSD 
1. 
3mg 
3.02  ± 0.000027 0.0090 101.91 ± 0.472 0.0046 
2. 2.94 ± 0.000035 0.0118 99.80 ± 0.315 0.0031 
3. 3.05  ± 0.000044 0.0147 99.91 ± 0.472 0.0047 
            
*Each value is the mean of three determinations. 
Table 30: Recovery studies of CNP using AAC 
     
*Each value is the mean of three determinations 
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20% 
3mg 
0.6 3.57 0.59 19.82 98.50 ± 0.380 0.0191 
40 % 1.2 4.17 1.19 39.80 99.38 ± 0.900 0.0225 
100 % 3.0 5.97 2.99 99.76 100.07 ± 1.690 0.0170 
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Colorimetric estimation of Omeprazole by Redox with complexation 
Method (Basavaiah K., 2007) 
 
The visible spectrophotometric studies of OME is based on the oxidation of OME 
by excess of bromine and  indirectly determining the amount of OME using FAS and 
1,10 phenanthroline in Method A and ammonium thiocyanate in Method B. 
 
Preparation of reagents 
Potassium bromate – bromide mixture  
100mg of potassium bromate and 1g of potassium bromide was dissolved in 10 mL of 
distilled water and made up to volume in a 100 mL volumetric flask. Appropriate dilution 
of the stock solution was made to obtain a concentration of 35 and 20 µg/mL to be used 
in method A and B respectively.  
Ferrous ammonium sulphate 
400mg of FAS was dissolved in 50 ml of distilled water, to that 1 mL of dilute sulphuric 
acid was added and made up to 100 mL with distilled water. Further dilutions were made 
to obtain a concentration of 350 µg/mL and 400 µg/mL of FAS to be used in method A 
and B respectively. 
1, 10 - Phenanthroline 
250 mg of 1, 10 – Phenanthroline was dissolved in distilled water with the aid of heat and 
made up to volume in 100 mL volumetric flask. 
Hydrochloric acid (5M-) 
About 43mL of concentrated hydrochloric acid was made up to 100mL with distilled 
water. 
Hydrochloric acid (1M) 
About 85mL of concentrated hydrochloric acid was made up to 100mL with distilled 
water.  
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Ammonia solution (50 %) 
About 50 ml of strong ammonia solution was added to 50 ml of distilled water.  
Ammonium thio cyanate (3 mol L-1)       
23g of ammonium thiocyanate was dissolved and made up to 100mL with distilled water. 
 Hydrochloric acid (5 mol L-1-) 
 About 15.5mL of concentrated hydrochloric acid was made up to 1000mL with distilled 
water. 
Preparation of standard stock solution  
            Accurately weighed quantity of standard OME was dissolved in methanol and 
shaken for 15 minutes, and then the volume is made up with 1M hydrochloric acid to 
obtain a final stock concentration of 100µg/mL.  
 
 
METHOD C using 1, 10- Phenanthroline 
Spectral characterization and Linearity Establishment 
           . The stock solution was further diluted with distilled water to obtain a working 
standard solution of concentration 2µg/mL. Transferred 1-3.5mL of the working standard 
solution (2µg/mL) in to a series of 25 ml volumetric flask. To each was added 2.5mL of 
potassium bromate – bromide mixture (35µg/ml) using a burette and 2.5mL of 
hydrochloric acid (5M), stoppered immediately, shaken well and kept aside for 5 minutes. 
Later, 2.5mL of FAS (350µg/ml) was added, shaken well and allowed to stand for fifteen 
minutes until the reaction is completed. To this 2.5mL of 1, 10- phenanthroline was 
added which gave blood red coloured chromogen. Finally the solutions were made up to 
volume with distilled water. The absorbance was scanned between 350-800nm against 
reagent blank. The red coloured chromogen gave maximum absorbance at 510 nm.  
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Reaction Mechanism (Vogel, 2007) 
I. Oxidation 
    KBrO3 + 5KBr + 6HCl                                    6 KCl + 3Br2 + 3H2O 
                                                           Br2 / HCl   
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        II. Complexation 
                                                 (o) 
            Fe 2+  +   Br2  (Excess)                                    Fe 3+  +2 Br   
               (ferrous)                                                         (ferric) 
Fe 2+  +      N N                                      Fe[(C12H8N2)3]2+ 
  (ferrous)                                                           Red chromogen (ferroin) 
                
Omeprazole 
Oxidised form of Omeprazole 
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The reaction is based on the oxidation of OME by the insitu liberated bromine 
during the reaction between excess bromate-bromide and hydrochloric acid. The 
unreacted bromine left after oxidation of OME is determined indirectly by the oxidation 
of large excess of FAS to ferric ammonium sulphate. The unreacted FAS on treatment 
with 1, 10-phenanthroline forms a blood red complex which is a very well known 
complexation reaction used for the estimation of iron in the ferrous state. The complex is 
formed only in an alkaline medium by the addition of ammonia solution. The complex 
showed λmax at 510 nm. 
 
Optimisation 
      The strength and volume of hydrochloric acid and bromate-bromide mixture were 
optimised. Any change in the volume of the reagent resulted in either insufficient 
liberation or large excess of bromine which did not give any good response. 1ml of 5M 
hydrochloric acid and 2.5ml of bromate –bromide mixture and 2.5ml of 350 µg/mL of 
FAS was thus selected for the complete reduction of the unreacted bromine. Moreover, 
2.5mL of 1, 10- phenanthroline was required for the complete complexation of the  
excess unreacted FAS.  The complex is formed only in an alkaline medium which is 
provided by the addition of 2mL of ammonia solution. Any more increase in volume of 
the ammonia solution, drastically increases the pH of the solution resulting in the 
instability of the complex. The red coloured chromogen was obtained which showed a 
maximum absorbance at 510 nm. Higher concentration of the analyte, required very high 
concentration and large excess of the bromate-bromide mixture.  
The method obeyed Beer’s law at a concentration of 1-3.5 µg/mL of OME. A 
graph was plotted using absorbance against concentration and linear regression analysis 
was applied to determine the linearity (Table-31).  
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The overlain spectra for the linearity studies are shown in Fig-23. 
 
Fig 23: Overlain spectra of OME –1,10phenanthroline 
 
 
Table 31: Absorbance of OME –1,10phenanthroline 
 
 
 
 
 
 
 
 
 
                      *Each value is the mean of three determinations 
 
 
Sl. No. Concentration (in µg/mL) Absorbance* 
1 1 0.043 
2 1.5 0.126 
3 2 0.187 
4 2.5 0.254 
5 3 0.317 
6 3.5 0.402 
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The correlation coefficient was found to be 0.997 as shown in Fig-24. 
 
 
Fig 24: Calibration chart of OME–1,10phenanthroline 
 
Analysis of Formulation 
  
            Enteric coated granules of OME was accurately weighed and crushed to fine 
powder. Powder equivalent to 50mg of OME was weighed in a 100ml volumetric flask, 
shaken vigorously with sufficient amount of methanol for half an hour and finally made 
up to volume with 1M hydrochloric acid to obtain a concentration of 100µg/mL. The 
solution was filtered through Whatmann filter paper No.41. First few mL of the filtrate 
was discarded and the filtrate was appropriately diluted to obtain a concentration of 
10µg/mL with distilled water. Transferred 3 mL of the first dilution (10µg/mL) to a 
25mL volumetric flask and the same procedure for standard OME was followed. The 
absorbance of the resulting solution was measured at 510nm. 
 
The amount of drug present was calculated and presented in Table-32. The 
percentage recovered was calculated and the results obtained are presented in Table-33. 
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Table 32: Results of Assay (OME–1,10phenanthroline) 
Sl. No. Label Claim 
Amount Present 
(in mg) ± SD* RSD % Purity ± SD RSD 
1. 
20mg 
20.0 ± 0.0003 0.0153 100.09 ± 1.530 0.0153 
2. 20.0 ± 0.0002 0.0101 100.09 ± 1.012 0.010 
3. 20.2 ± 0.0002 0.0100 101.17 ± 1.012 0.010 
            
             *Each value is the mean of three determinations. 
 
Table 33: Recovery studies (OME–1,10phenanthroline) 
    
   *Each value is the mean of three determinations 
 
 
METHOD D using Ammonium thio cyanate 
Spectral characterization and Linearity Establishment 
             The stock solution was further diluted with distilled water to obtain a working 
standard solution of concentration 2 µg/mL. Transferred 0.5-1 mL of the working 
standard solution (2µg/mL) into a series of 25 ml volumetric flask. To each was added 
2.5 mL of potassium bromate – bromide mixture (40µg/ml) using a burette and 2.5mL of 
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20% 
20mg 
4 24.13 4.05 20.26 101.30 ± 0.642 0.0317 
50% 10 28.22 8.10 40.25 100.62 ± 0.642 0.0159 
100% 20 39.99 19.87 99.33 99.33 ± 0.642 0.0650 
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hydrochloric acid (5M), stoppered immediately, shaken well and kept aside for 5 
minutes. To the reaction mixtures, 2.5 ml of FAS was added (400 µg/ml), shaken well 
and allowed to stand for fifteen minutes until the reaction is completed. To this of 2.5mL 
of 3 mol L-1 ammonium thiocyanate was added which gave a blood red coloured 
chromogen. Finally the solutions were made up to volume with distilled water. The 
absorbance was scanned between 350-800nm against reagent blank. The red coloured 
chromogen gave maximum absorbance at 477nm. 
Reaction Mechanism: 
I. Oxidation 
    KBrO3 + 5KBr + 6HCl                                       6 KCl + 3Br2 + 3H2 
                  
H3CO
N
N
H
S
O
N
CH3 CH3
OCH3                                                              
                                                            Br2       (O) 
                                     
                        
H3CO
N
N
H
S
O
N
CH3 CH3
OCH3
O
 
                            
                                                                
 
Oxidised form of Omeprazole 
Omeprazole 
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II. Complexation 
                                                 (o) 
            Fe 2+  +   Br2  (Excess)                                    Fe 3+  +2 Br – 
(ferrous)                                                         (ferric) 
 
Fe 3+  +  3SCN–                                              Fe(SCN)3 
                                                                       Red chromogen  
                                                                      (ferric thiocyanate)  
 
The reaction is based on the oxidation of OME by the insitu liberated bromine 
during the reaction between excess bromate-bromide and hydrochloric acid. The 
unreacted bromine left after oxidation of OME is determined indirectly by the oxidation 
of FAS to ferric ammonium sulphate. This in turn is complexed with ammonium 
thiocyanate to form a blood red complex of ferric thio cyanate which showed the 
absorption maximum at 477nm. When a known excess amount of bromate-bromide 
mixture is allowed to react with increasing amount of OME, there occurs decrease in the 
amount of bromine for oxidation of FAS to ferric ammonium sulphate resulting in a 
negative slope in the calibration chart. 
 
Optimisation 
The strength and volume of hydrochloric acid and bromate-bromide mixture was 
optimised. 1ml of 5M hydrochloric acid and 2ml of bromate –bromide mixture and 2ml 
of 400µg/mL of FAS was selected for the completion of the redox reaction. Moreover, 
1mL of 3 molL-1 ammonium thio cyanate was required for the complete complexation of 
oxidised ferric ammonium sulphate to ferric thio cyanate. The ferric thio cyanate 
complex is blood red in colour and was found to be stable for 3 hrs. It showed maximum 
absorbance at 470 nm. Higher concentration of the analyte, required very high 
concentration and large excess of the bromate-bromide mixture. The above developed 
method obeyed Beer’s law at the concentration of 0.5-2.5µg/ml of OME which showed a 
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gradual  decrease  in  the  concentration  of  the  bromine  by  the  linear  negative  slope 
Table-34. The overlain spectra is shown in Fig-25. 
 
Fig 25: Overlain spectra of OME –Ammonium thio cyanate 
 
Table 34: Absorbance of OME –Ammoiun thio cyanate 
 
 
                                   
 
 
 
 
 
*Each value is the mean of three determinations 
 
 
Sl. No. Concentration (in µg/mL) Absorbance* 
1 0.5 0.279 
2 1 0.247 
3 1.5 0.215 
4 2 0.185 
5 2.5 0.158 
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The correlation coefficient was within the limit as 0.998 Fig-26. 
 
Fig 26: Calibration chart of OME-Ammonium thio cyanate 
 
Analysis of Formulation 
 Enteric coated granules of OME was accurately weighed and crushed to fine 
powder. Powder equivalent to 50mg of OME was weighed in a 100ml volumetric flask, 
shaken vigorously with sufficient amount of methanol for half an hour and finally made 
up to volume with 1M hydrochloric acid to obtain a concentration of 100µg/mL. The 
solution was filtered through Whatmann filter paper No.41. First few mL of the filtrate 
was discarded and the filtrate was appropriately diluted to obtain a concentration of 
10µg/mL with distilled water. Transferred 3 mL of the first dilution (10µg/mL) to a 
25mL volumetric flask and the same procedure for standard OME was followed. The 
absorbance of the resulting solution was measured at 477nm. The amount of drug present 
was calculated and the results obtained are presented in Table-35.  
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     Table 35: Results of Assay of OME by Ammonium thio cyanate 
 
Sl. 
No. 
Label 
Claim 
Amount present 
(in mg) ± SD* RSD % Purity ± SD RSD 
1. 
20mg 
20.0 ± 0.0003 0.0153 100.09 ± 1.530 0.0153 
2. 20.0 ± 0.0002 0.0101 100.09 ± 1.012 0.010 
3. 20.2 ± 0.0002 0.0100 101.17 ± 1.012 0.010 
           
  *Each value is the mean of three determinations. 
  
 
 The percentage recovered was calculated and the results obtained are presented in 
Table-36. 
 
Table 36: Recovery studies of OME by Ammonium thio cyanate 
     
   *Each value is the mean of three determinations 
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20% 
20mg 
4 24.13 3.94 20.40 100.20 ± 0.964 0.0473 
50% 10 28.02 7.90 39.49 98.73 ± 0.964 0.0244 
100% 20 40.22 20.03 100.16 100.16 ± 0.964 0.0096 
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High Performance Liquid Chromatography Method 
The technique of high performance liquid chromatography (HPLC) was 
developed in the late 1960s and early 1970s from knowledge of the theoretical 
principles. It is the most widely used of all the analytical separation techniques, owing to 
its sensitivity, its ready adaptability to accurate quantitative determinations, its suitability 
for separating non-volatile species and its widespread applicability to substance like 
aminoacids, proteins, drugs, antibiotics, steroids etc, that are of prime interest to many 
fields of science (Beckett AH, 1997).  
The technique is based on the modes of separation. (Willard, 1986) 
Adsorption: This method separates analytes based on their affinity for a polar stationary 
surface such as silica. 
Partition: This method separates analytes based on their affinity towards liquid 
stationary coated on an inert support that is immiscible with the eluent. 
Ion exchange: In this method the retention is based on the attraction between solute ions 
and charged sites bound to the stationary phase. Ions of the same charge are excluded.  
Size-exclusion also known as gel permeation chromatography or gel filtration 
chromatography, separates particles on the basis of size. It is generally a low resolution 
chromatography. 
Modes of chromatography (Mendham, et al., 2002) 
 Normal phase chromatography is the chromatography in which the stationary 
phase is more polar than the mobile phase. Sample retention in normal phase 
chromatographic technique increases as the polarity of the mobile phase decreases. 
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Reversed phase HPLC (RP-HPLC) has a non-polar stationary phase and an 
aqueous, moderately polar mobile phase but it differs from column chromatography in 
that the mobile phase is pumped through the packed column under high pressure. The 
mode of operation of this system is isocratic, i.e. one particular solvent or mixture is 
pumped throughout the analysis.  
HPLC as compared with the classical LC technique is characterized by: 
 high resolution 
 small diameter (4.6 mm), stainless steel, glass or titanium columns; 
 column packing with very small (3, 5 and 10 μm) particles; 
 relatively high inlet pressures and controlled flow of the mobile phase; 
 continuous flow detectors capable of handling small flow rates and detecting very 
small amounts; 
 rapid analysis. 
Separation/Elution technique (James W. Munson, 2001) 
A separation in which the mobile phase composition remains constant throughout 
the procedure is termed isocratic (meaning constant composition). If the mobile phase 
composition does not remain constant throughout the separation process, then that 
procedure is termed as gradient. 
Quantitative Analysis (Sharma B.K, 1994) 
Quantification by HPLC involves the measurement of peak height (or) peak area. 
Similar to UV quantification, linearity concentration is established for the standard 
analyte and calibration curve is plotted by taking peak height (or) peak area verses 
concentration.  The plot should be a linear line essentially passing through the origin. 
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The quantification techniques include External standard method, Internal standard 
method and standard addition method. 
External standard method is the simplest and accurate method. Linearity is established 
for the standard drug concentration is determined. A concentration of the test sample 
essentially lying in the linearity range is also studied and interpolated on the calibration 
chart to determine the sample concentration. 
Concentration of the analyte is determined by 
   
 
The amount present in the pharmaceutical formulation is calculated using the formula: 
 
 
 
 
REVERSE PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
Instrument 
1. Shimadzu prominence 
2. UV-Visible Detector (SPD 20A) 
3. Auto sampler 
4. Isocratic (LC-20AT) pump 
5. Rheodyne Valve injector with 20 µl fixed loop 
      6.   Chromatographic Column- Phenomenx Gemini, C18 
                                                Dimensions:  250 x 4.60 mm 5μ 
 
Reagents and Chemicals 
Methanol HPLC grade 
Acetonitrile HPLC grade 
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Potassium dihydrogen phosphate AR grade 
Omeprazole granules 
Cinitapride hydrogen tartarate  
Formulated Sample 
 
Reverse phase-HPLC 
As the analyte is more polar RP-HPLC method was selected. 
 
Preparation of mobile phase 
Phosphate buffer, acetonitrile and methanol were mixed in the ratio of 40:20:40 
(pH-7), filtered through 0.2µ membrane filter. 
Selection of wave length  
A known concentration of standard CNP and OME were prepared in methanol. 
The solutions were further diluted appropriately with the mobile phase to obtain a 
concentration of 10 µg/mL and scanned in the UV region against mobile phase as the 
blank. The λmax was observed at 262nm for CNP and 301nm for OME. On analyzing the 
λmax using different ratios of mobile phase and buffer of varied pH, it showed no 
significant change. Hence, 262 and 301nm were selected as the detection wavelength for 
the estimation CNP and OME respectively by RP-HPLC.    
Determination of retention time  
The diluent was injected first to determine the absence of any interference with 
the baseline. The retention time of drugs were determined by injecting the standards 
CNP and OME. The retention time for CNP and OME was found to 6.5 minutes and 3.2 
minutes respectively.   
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Optimization of the chromatographic condition 
The chromatographic conditions were optimized using the standard drugs CNP 
and OME. The optimization procedure involves the optimization of mobile phase in 
relation to its compatibility to the system suitability parameters as per ICH guidelines. 
 
Effect of different ratios of mobile phase and flow rate on separation 
 Both the drugs were studied using different ratios of mobile phase like 
50:20:30%v/v, 20: 20: 60%v/v and 40:20:40%v/v of acetonitrile: methanol: phosphate 
buffer pH-7.  The shape and symmetry of the peak, the retention times were good and 
acceptable only in 40:20:40%v/v mobile phase. So, that was selected for the study of the 
drugs by HPLC. Separation of both CNP and OME were tried at different flow rates i.e. 
1.5, 1.8, 2.0, and 2.5 mL/min and the chromatograms were recorded. The peak was very 
sharp at 2.0mL/min, and the retention times were found to be 6.5 minutes and 3.2 
minutes for CNP and OME respectively. 
 Effect of pH of mobile phase  
 The different pH solutions were tried i.e. 6.5, 7.0, 7.5, and the chromatograms 
were recorded. On  comparing  the  chromatograms  obtained,  it  was  found  that  only 
at pH 7, the peak was very sharp for both CNP and OME.  
Optimized chromatographic conditions  
 The following chromatographic conditions were fixed to study the separation of 
both CNP and OME standard drugs separately. 
Operation mode : Isocratic 
Stationary phase : Phenomenex Gemini, C18 Column (250 mm × 4.6 mm i.d., 5 µ) 
Mobile phase : Acetonitrile, Methanol and Phosphate buffer (pH-7) (40:20:20) 
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Wavelength for OME : 301 nm  
Wavelength for CNP : 262 nm  
Flow rate : 2.0 mL/min 
Temperature : ambient 
Injection volume : 20 μL 
Quantification method : External Standard Calibration Method 
Run time : 3.2 minutes for OME and 6.5 minutes for CNP 
 
Determination of CNP and OME in bulk and oral dosage form 
 The capsule dosage form contains CNP as extended release tablet and OME as 
enteric coated granules. Thus both the components were analyzed as separate entities. 
CINITAPRIDE 
Preparation of standard solutions and Establishment of Linearity 
30mg of standard CNP was accurately weighed and dissolved in methanol and 
made up to volume with the same in a 25mL volumetric flask to get a concentration of 
0.6 mg/mL. The solution was then filtered through 0.2µ membrane filter.  
Establishment of Linearity 
Aliquot quantity of the standard solution (0.6 mg/mL) of CNP was serially 
diluted with the mobile phase to get a concentration range of 84µg/mL to132µg/mL. 
Linearity was established in this concentration range and calibration curve was 
constructed, by injecting 20µl of the standard solutions. The eluate was detected at 
262nm and the chromatogram was recorded. Linearity data are presented in the Table-37. 
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Table 37: Peak area at different concentration of CNP 
Sl. No. Concentration µg/mL Peak area 
1. 84 1670.30 
2. 96 1863.70 
3. 108 2110.90 
4. 120 2325.40 
5. 132 2571.90 
 
Calibration graph 
The peak area was plotted against concentration and shown in Fig-27 
 
  Fig 27: Calibration chart of CNP- Peak area vs concentration  
Assay of formulation 
Twenty tablets of CNP from the formulation were accurately weighed and 
powdered. The powder equivalent to 6mg of CNP was accurately weighed, dissolved in 
methanol with the aid of ultrasonication for 15minutes and made up to volume (10mL) 
with the methanol. The solution was further diluted with mobile phase to obtain a 
concentration of 0.12 mg /mL. The solution was then filtered through 0.2µ membrane 
filter and injected into the column. The eluate was detected at 262nm and the 
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chromatogram was recorded. The amount present per capsule was calculated using the 
formula and the assay results are tabulated in Table-38. 
The optimized chromatogram of CNP which reveals the retention time (Rt) to be 
6.5 as shown in fig-28 and fig-29.  
 
Fig 28: Chromatogram of Sample CNP 
     
      Table 38: Results of Assay of CNP 
 
Sl. No. Label Claim 
Amount 
Present 
(in mg)  
% Purity ± SD RSD 
1. 
3 mg 
2.97 99.16 
0.7856 0.0078 2. 2.97 99.16 
3. 3.02 100.83 
           
  *Each value is the mean of three determinations. 
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Fig 29: Chromatogram of CNP – showing Rt = 6.5 minutes 
 
Recovery studies 
To 5mL of preanalysed sample stock solution (0.6mg/mL) 2.5 mL of standard 
stock solution (0.6mg/mL) was added and made up to 25 mL in a volumetric flask. The 
solution was then filtered and injected in to the column. The eluate was detected at 
262nm and the chromatogram was recorded. The procedure was repeated three times. 
Table 39:  Results of recovery studies  
     
   *Each value is the mean of three determinations. 
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3 1.5 
4.45 1.41 47.10 98.89 
0.4545 0.0045 4.50 1.46 48.76 100.00 
4.47 1.43 47.93 99.44 
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OMEPRAZOLE 
Preparation of standard solutions and Establishment of Linearity 
110mg of standard OME were accurately weighed and transferred to a 50 mL 
volumetric flask, dissolved in mobile phase and made up to volume with the same to get 
a concentration of 2.2mg/mL. The solution was filtered through 0.2µ membrane filter 
and used further. 
Evaluation of Linearity 
Aliquot quantity of the standard solution (2.2mg/mL) of OME was serially 
diluted with the mobile phase to get a concentration range of 154µg/mL to 242µg/mL. 
Linearity was established in this concentration range and calibration curve was 
constructed, by injecting 20µl of the standard solutions. The eluate was detected at 
301nm and the chromatogram was recorded. Linearity data are presented in the Table-40. 
The peak area was plotted against concentration and the linearity was assessed using 
regression analysis. 
Table 40: Peak area at different concentration of OME 
Sl. No. Concentration  (µg/mL) Peak area 
1. 154 1842.56 
2. 176 2117.85 
3. 198 2386.50 
4. 220 2633.88 
5. 242 2889.10 
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Assay of formulation 
Enteric coated granules of OME was accurately weighed and crushed to fine 
powder. Powder equivalent to 110mg of OME was weighed in a 50ml volumetric flask, 
dissolved in mobile phase with the aid of ultrasonication for 15minutes and made up to 
volume with the same to obtain a concentration of 11.74mg/mL. The solution was further 
diluted to obtain a concentration of 1.1mg/mL. The final dilution was then filtered 
through 0.2µ membrane filter and 20 µl was injected into the column. The eluate was 
detected at 301nm and the chromatogram was recorded. 
The optimized chromatogram of OME which reveals the retention time (Rt) to be 
3.2 as shown  in fig-30 and fig-31.     
 
 
Fig 30: Chromatogram of sample OME 
The amount of drug present was calculated and presented in Table-41. The 
percentage recovered was calculated and the results obtained are presented in Table-42.  
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Fig 31: Chromatogram of OME – showing Rt = 3.2 minutes 
 
   
     Table 41: Results of Assay of OME 
Sl. No. Label Claim 
Amount 
Present 
(in mg)  
% Purity ± SD RSD 
1. 
20 mg 
20.08 100.39 
0.2151 0.0021 2. 20.17 100.85 
3. 20.17 100.39 
            
           *Each value is the mean of three determinations 
 
Recovery studies 
To 5mL of preanalysed sample stock solution (2mg/mL) 2.5 mL of standard 
stock solution (2mg/mL) was added and made up to 50 mL in a volumetric flask. The 
solution was then filtered and injected in to the column. The eluate was detected at 
301nm and the chromatogram was recorded. 
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Table 42: Results of Recovery studies 
     
*Each value is the mean of three determinations. 
Limit of Detection (LOD) and Limit of Quantification (LOQ) 
 Calibration of standard (CNP and OME) was repeated for three times.  The limit 
of detection and limit of quantification was calculated by using the average value of 
slope and standard deviation of intercept.  
Accuracy (Mousumi Kar., et al., 2009) 
The accuracy of the developed method was determined by performing recovery 
studies using the standard addition technique. A known amount of the standard drugs 
were added to the respective samples and the chromatogram was recorded for the same. 
Specificity (Lokesh Singh., et al., (2011)  
The specificity test of the proposed method demonstrated that the excipients from 
tablets do not interfere in the drug peak. Furthermore, well shaped peaks indicate the 
specificity of the method. Better resolution was found for the drug peak with no 
interference proved that the method was found to be selective to the drug. 
System suitability parameters (Lokesh Singh., et al., 2011) 
The system suitability studies were carried out as specified in ICH guidelines and 
USP.  The results are presented in Table-45. 
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Results and 
Discussion 
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RESULTS AND DISCISSION 
Ultra Violet Spectroscopic Method 
 
 In Standard absorbance method, OME was found to be very freely soluble in 
methanol and it showed an absorption maximum at 301 nm and was subject to 
quantification. The drug obeyed Beer’s law in the concentration range of 4-20 µg/mL. 
The linearity was assessed by the regression analysis and was found to be 0.054x+0.000. 
The correlation coefficient was found to be 0.999 which was within the limit and showed 
a good linearity between concentration and absorbance. The percentage recovery 
obtained was found to be between 100.4% to 101.3% (Table-3) indicating the accuracy 
of the method. The result of the analysis of formulation from the (Table-2) shows that 
the proposed method is in good agreement with the labeled amount of drug. 
 Similarly CNP was also found to be freely soluble in methanol and it showed an 
absorption maximum at 262 nm and subject to quantification. The standard drug was 
subjected to linearity studies and it obeyed Beer’s law in the concentration range of 4–20 
µg/mL. The graph was linear from 4–20µg/mL. Above 20µg/mL it showed negative 
deviation from Beer’s law. The linearity was assessed by the regression analysis and was 
found to be 0.056x+0.000. The correlation coefficient was found to be 1 which showed a 
good linearity between concentration and absorbance. The percentage recovery obtained 
was found to be between 101.2% to 101.8% (Table-6) indicating the accuracy of the 
method. The result of the analysis of formulation from the (Table-5) shows that the 
proposed method is in good agreement with the labeled amount of drug. 
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 In AUC method, the normal spectra were subjected to AUC mode. The AUC 
from wavelengths 281-328.8nm were selected to estimate the amount of OME present in 
the capsule dosage form. Similarly AUC from wavelengths 239.8 and 296.4nm were 
selected for CNP. The area under curves was noted and the calibration curve was plotted 
against concentration for both OME and CNP. The respective charts were found to be 
linear and the linearity was assessed by the regression analysis. The correlation 
coefficient was determined to be 0.9990 for both OME and CNP which showed a good 
linearity between concentration and area. The sample AUCs were interpolated on the 
respective linearity charts and the concentrations were determined. The percentage 
recovery obtained was found to be between 100.78% to 101.56% for OME and 100.68% 
to 101.57% for CNP which indicates the accuracy of the proposed method and proves the 
non-interference of excipients used in formulation. The result of the analysis of 
formulation from the (Table-8 & Table-11) shows that the proposed method is in good 
agreement with the labeled amount of drug. 
 
 First derivative spectroscopy method is simple, accurate, rapid and 
reproducible. When the first derivative method is applied to the estimation of OME and 
CNP, it produced good results without any interference from excipients. The zero order 
spectra obtained in the linearity characterization and method A were derivatized to get 
first order spectra for both OME and CNP. The regression analysis method was used to 
determine the linearity of response with concentration. It reveals the correlation 
coefficient to be 0.998 for OME and 0.999 for CNP. This shows the accuracy of the 
method. The sample concentrations were arrived by interpolation of their amplitudes in 
the respective charts.  
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 Second derivative spectroscopy is applied to OME and CNP estimation, it 
produced good results without any interference from excipients. The zero order spectra 
obtained in the linearity characterization and method A were derivatized to get second 
order spectra for both OME and CNP. The sample concentrations were arrived by 
interpolation of their amplitudes in the respective charts. The regression analysis method 
was used to determine the linearity of response with concentration. It reveals the 
correlation coefficient to be 0.999 for both OME and CNP. This method showed good 
accuracy and repeatability. 
 The optical parameters for all the above methods are presented in Table-43 
 
VISIBLE SPECTROSCOPY 
Two colorimetric methods were developed for the estimation of CNP and OME. 
Colorimetric methods of CNP are based on the diazotization followed by complexation 
method. In these methods the estimation is based on the formation of diazonium salt with 
nitrous acid and concentrated hydrochloric acid (as the analyte posses primary aromatic 
amino group) and then complexing with EAA in method A and with AAC in method B 
yielding a reddish orange chromogen which showed maximum absorption at 392.5 and 
399nm respectively. The calibration curve was linear in the range of 10-60μg/mL for 
both the methods. The correlation coefficient for method A and B was found to be 0.999 
and 0.998 respectively which indicates the good correlation between concentration and 
absorbance. The result from the analysis of formulation for method A and B were found 
to be between 98 to102 which indicates that the proposed methods are in good agreement 
with the labeled amount. From the recovery studies carried out using standard addition 
method, the accuracy of the proposed methods can be determined. The results revealed 
that there was no interference of excipients. 
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Colorimetric methods of OME are based on redox method. The correlation 
coefficient was found to be 0.997 and 0.998 for method A and B respectively; this 
indicates the good linearity between concentration and absorbance. The linearity was 
assessed by the regression analysis. The percentage recovery obtained was found to be 
between 98% to 101% for both the methods which indicates the accuracy of the method. 
The result from the analysis of formulation for method A and B were found to be 
between 98 to102 which indicates that the proposed methods are in good agreement with 
the labeled amount. From the recovery studies carried out using standard addition 
method, the accuracy of the proposed methods can be determined. The results revealed 
that there was no interference of excipients. 
The optical parameters for all the four colorimetric methods are presented in 
Table-44. 
 
RP-HPLC 
In RP-HPLC method for analysis of CNP and OME mobile phase containing 
acetonitrile, methanol and phosphate buffer (pH-7) in the ratio 40:20:20 was chosen and 
the effluent was monitored at 262nm for CNP and 301nm for OME using UV-Visible 
detectors. The retention time for CNP and OME were found to be 6.5 and 3.2 minutes 
respectively. The drugs presented a good linearity at the range of 84µg/mL to132 µg/mL 
and 154µg/mL to 242µg/mL for CNP and OME respectively which assures that the 
proposed chromatographic conditions and the mobile phase were suitable for the 
estimation. The number of theoretical plates for CNP and OME was found to be 6497 
and 5080 respectively which confirms the column efficiency and nature of mobile phase. 
The low value of LOD and LOQ indicates the sensitivity of the method. The percentage 
purity for both the drugs was found to be between 98 to 100% which was in good 
agreement with the label claim of the sample. The accuracy (Mousumi Kar., et al., 2009) 
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of the developed method was determined by performing recovery studies using the 
standard addition technique. The analysis was performed thrice. The results of the 
recovery are shown in Table-45. The percentage recovery was found to be between 98.89 
to 100.00 % with S.D ± 0.4545 and RSD of 0.0045 for CNP and 99.50 % with S.D ± 
0.6937 for OME.  The specificity of the proposed method is confirmed by the well 
shaped peaks.  
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  Table 43: Optical parameters of CNP and OME 
Sl.  
No. Optical Parameter 
Cinitapride Omeprazole 
Method Method 
A B C D A B C D 
1. Wavelength λmax 262 nm 262nm 262nm 262nm 301nm 301nm 301nm 301nm 
2. Molar Absorptivity 22557.89 --- --- --- 18727.82 ---- ---- ---- 
3. Beer’s law limit (µg/mL) 4-20 4-20 4-20 4-20 4-20 4-20 4-20 4-20 
4. Regression Equation y = 0.056x + 0.000 
y = 
0.882x + 0.052 
y = 
0.346x + 0.092 
y = 
0.478x + 0.085 
y =  
0.054x + 0.000 
y = 
0.812x – 0.056 
y = 
0.181x - 0.028 
y = 
0.321x - 0.071 
5. 
 Slope 0.056 0.882 0.346 0.478 0.054 0.812 0.181 0.321 
6. Intercept 0.00029 0.052 0.092 0.085 0.001 –0.056 -0.028 -0.071 
7. Correlation Coefficient 1.0 0.999 0.999 0.999 1.0 0.999 0.998 0.999 
8. Sandell’s Sensitivity 0.0178 ---- --- --- 0.0184 ---- --- ---- 
9. LOD 0.03366 --- --- ---- 0.1394 ---- --- ---- 
10. LOQ 0.10200 ---- ---- ---- 0.4225 ---- --- --- 
11. RSD 0.0005 0.0062 0.0031 0.0031 0.0090 0.0051 0.0120 0.0060 
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Table 44: Optical parameters of CNP and OME 
Sl. No Optical Parameter 
 
Cinitapride 
 
Omeprazole 
Method Method 
A B A B 
1. Wavelength λmax 392.5 nm 399nm 510nm 477nm 
2. Molar absorptivity 8837.83 6571.97 31238.85 76271.03 
3. Beer’s law limit (µg/mL) 10-60 10-50 1-3.5  0.5-2.5 
4. Regression equation y=0.021x+ 0.006 y=0.015x + 0.011 y = 0.139x - 0.091 y = -0.060x+0.308 
5. 
 Slope 0.021 0.015 0.139 -0.060 
6. Intercept 0.006 0.011 -0.091 0.308 
 
7. Correlation coefficient 0.999 0.998 0.997 0.998 
8. Sandell’s Sensitivity 0.046 0.061 0.0123 0.0078 
9. LOD 4.40 5.18 -4.34 -33.43 
10. LOQ 13.33 15.68 -1.316 -10.13 
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  Table 45: System suitability parameters for CNP and OME 
 
 
 
 
 
 
 
 
 
Sl. No. Parameter Cinitapride Omeprazole 
1. Theoretical Plates 6497 5080 
2. Tailing factor 0.93 1.27 
3. Capacity factor 0 0 
4. Temperature of the column ambient ambient 
5. Retention time 6.5 minutes 3.2 minutes 
6. Correlation coefficient (r2) 1 1 
7. Linearity (μg/ml) 84-132 154-242 
8. Limit of Detection (LOD) (μg/mL) 1.5 3.3 
9. Limit of Quantitation (LOQ) (μg/mL) 5.3 11.1 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary and 
conclusion 
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SUMMARY AND CONCLUSION 
 
The present work entitled “METHOD DEVELOPMENT AND VALIDATION OF 
OMEPRAZOLE AND CINITAPRIDE BY UV-VISIBLE SPECTROPHOTOMETRY AND 
RP-HPLC IN ORAL SOLID DOSAGE FORM”. 
UV spectroscopic method, (method 1) was carried out to find out the content of 
Omeprazole and Cinitapride present in oral dosage form. In this method, the solutions 
are prepared by using methanol as solvent and further diluted using the same and 
scanned over the UV region. The λmax of OME was found to be 301nm and that of CNP 
was 262nm in methanol. The resultant spectra were analyzed and Beer’s concentration 
was found to be 4-20μg/mL. The %RSD < 1 proves the reproducibility of the method.  
Area under curve (method 2) was developed for the estimation of OME and CNP 
using the normal spectra or fundamental spectra obtained by method A. The area 
between the two selected wavelengths were noted and plotted against concentration to 
obtain the calibration curve from which the amount of OME and CNP were calculated. 
The percentage recoveries were found by the standard addition method and the results 
showed the accuracy of the proposed method. The low standard deviation obtained for 
both OME and CNP shows the precision of the method which in turn shows good 
reproducibility and repeatability of the method. 
First order and Second order derivative spectroscopy methods (3 and 4) were 
carried out with the help of derivative mode available as inbuilt software. 
 In these methods the zero order spectra were derivatized to get first and second 
order spectra The amplitudes were measured and plotted against concentrations. By 
interpolation the amount of drug present in the sample was found out. The amount found 
was in good agreement with the label claim and the precision level was satisfactory. 
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 Four different colorimetric methods have been developed for OME and CNP. 
 The two colorimetric methods for CNP are based on the formation of the 
diazonium salt with the primary aromatic amino group initially. Then the formed 
diazonium salt were coupled with ethyl aceto acetate in method A and with acetyl 
acetone in method B. On coupling a reddish orange coloured chromogen is formed 
which exhibits maximum absorption at 399 and 393nm respectively. The drug obeyed 
Beer’s law in the range of 10-60μg/mL for method A and method B at 10-50μg/mL. The 
results of analysis of formulation were close to label claim that proved the specificity of 
the methods. 
 The two colorimetric methods for OME initially involves the oxidation of OME to 
its sulfone analogue by the insitu generated excess bromine followed by determination of 
unreacted bromine. In method A, the residual bromine is treated with excess of ferrous 
ammonium sulphate and the remaining ferrous ammonium sulphate is complexed 1, 10 
phenanthroline at a raised pH, and measured at 510nm. Method B involves complexation 
of the excess ferrous ammonium sulphate to ferric thio cyanate by ammonium thio 
cyanate and measured at 470nm.  The drug obeyed Beer’s law in the range of 1-
3.5μg/mL for method A and method B at 0.5-1μg/mL. The respective optimized 
procedures were adopted for the assay, precision studies and recovery studies for both 
CNP and PNP. The results of analysis of formulation were close to label claim that 
proved the specificity of the methods. The results of the recovery studies reveal that the 
developed methods indicate that there is no interference due to excipients.  
 In RP-HPLC method C18 column was used for the estimation of OME and CNP. 
By trial and error, the mobile phase containing acetonitrile: methanol: phosphate buffer 
in the ratio of 40:20:40%v/v at a flow rate of 1.2mL/min was chosen. The 
chromatographic conditions were optimized and the effluent was monitored at 301nm for 
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OME and at 262 for CNP. CNP showed retention time at 6.5 minutes and OME at 3.2 
minutes. A calibration chart was constructed using peak area versus concentration. The 
assay, precision and recovery studies were performed. The results revealed that there was 
no interference of excipients. The %RSD values were < 1 which proved the 
reproducibility and specificity of the method and it can be used for routine analysis.  
 The spectrophotometric methods developed for the estimation of OME and CNP 
were accurate, simple, precise, rapid and economical. All the methods have shown good 
precision and accuracy. The low % RSD values in recovery studies for all the above 
methods indicate that there is no interference due to excipients used in the formulations. 
 Hence it is concluded that the developed UV – Visible and RP-HPLC methods 
could be effectively used for the routine analysis of Cinitapride and Omeprazole in 
pharmaceutical dosage formulation.  
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